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CD5 is a member of scavenger receptor cysteine-rich superfamily that is expressed 
primarily on T cells. It can attenuate T-cell receptor signaling and impair cytotoxic T 
lymphocyte (CTL) activation and is a therapeutic targetable tumour antigen 
expressed on leukemic T and B cells. However, the potential therapeutic effect of 
functionally blocking CD5 to increase T cell anti-tumour activity against tumours 
(including solid tumours) has not been explored. CD5- solid tumours in CD5 
knockout mice display increased in anti-tumour immunity. Hence, blocking CD5 
function may have a potential therapeutic effect by enhancing CTL function. Here, I 
assessed CD5 levels in T cell subsets in different organs in mice bearing syngeneic 
4T1 breast tumour homografts and determined the association between CD5 and 
increased CD69 and PD-1 (markers of T cell activation and exhaustion) by flow 
cytometry. I report that CD5 levels in T cells was higher in peripheral organs than in 
lymphocytes infiltrated into tumours, and that CD5high T cells from peripheral organs 
exhibited higher levels of activation and exhaustion than CD5low T cells from the 
same organs. Interestingly, among the population of tumour-infiltrated lymphocyte 
subtypes, CD8+ T cells with low CD5 were activated to a higher level than CD8+ T 
cells with high CD5, with concomitantly increased exhaustion markers. Thus, 
differential CD5 levels among T cells in tumours and lymphoid organs can be 
associated with different levels of T cell activation and exhaustion, suggesting that 
CD5 could be a therapeutic target for immunotherapeutic activation in cancer 
therapy. I then studied the effect on primary T cell effector function of targeting CD5 
ex vivo using an anti-CD5 MAb. The result showed enhanced cytotoxic T cell 
capacity to respond to activation and enhanced the capacity of CD8+ T cells to kill 
4T1-mouse tumour cells in an ex vivo assay. These data support the potential of 
blockade of CD5 function to enhance T cell-mediated anti-tumour immunity. Based 
on these results I tested anti-CD5 in vivo as a single agent and in combination with 
other drugs and found a significant increase in activation and effector function of T 
cells: an effect that resulted in decreased 4T1 tumour homograft growth in vivo. 
These data suggest potential use of anti-CD5 MAb to enhance immune activation to 
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 Summary for lay audience 
T cells are an important part of the immune system, containing molecules that 
participate in recognizing foreign substances (antigens) including antigens that arise 
in cancer cells. When antigens stimulate those molecules, they activate T cells to 
recognize and kill the foreign organisms that contain those antigens (including 
cancer cells that contain unusual molecules that act as antigens). On the other hand, 
T cells also contain proteins that control their degree of activation by limiting their 
response to antigen recognitions: those proteins are termed “inhibitory receptors”. 
CD5 is such a receptor, expressed mainly on T cells, that limits T cell capacity to 
undergo activation in response to recognition of tumour antigen. Other studies have 
shown that mice with deleted CD5 and intact immune systems had delayed growth 
of transplanted tumours, suggesting that loss of CD5 can lead to increased immune 
activation in response to cancer cell antigen recognition, and immune cell-mediated 
attack and destruction of cancer cells resulting in slower cancer growth. I propose 
that blocking CD5 will coax T cells into better anti-cancer action, both as a treatment 
applied alone and in combination with already-approved immunotherapies. In this 
thesis, I describe my study of the correlation between CD5 level and T cell activation 
and exhaustion, and my assessment of dynamic CD5 expression among peripheral 
organs. I also inhibited CD5 on T cells obtained from mouse spleens using an anti-
CD5 blocking antibody, a step taken to make them more active in recognizing and 
killing cancer cells. I found a significant increase in T cell effector function following 
treatment with a blocking anti-CD5 antibody and, based on these results, I then 
moved on to test the efficacy of this drug to treat mice with fully functional immune 
systems and transplanted mouse breast tumours. Treating mice with anti-CD5 
antibody increased T cell activation function in spleen, lymph node and tumour. 
Furthermore, tumour growth was delayed by the treatment. These findings suggest 
that treatment with anti-CD5 MAb can result in increased T cell effector function and 
reduced tumour homograft growth. Further investigation of reduction of CD5 in 
combination with other immunotherapy approaches may enhance anti-cancer 
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Chapter 1  
1. Introduction  
Part of this chapter has been submitted for consideration as a mini-review article 
titled “CD5 as a Targetable Antigen in Solid and Non-Solid Tumours” in the 
European Journal of Immunology.  
1.1 Cancer immunity 
Early evidence suggesting a role for the human immune system in response to, 
and treatment of tumours was reported in 1891 when William Coley, known 
today as the “Father of Immunotherapy”, injected live bacteria as an immune 
activator in treatment of cancer patients (1). He used streptococcal bacteria that 
causes a cellulitis infection of the superficial layer of skin known as erysipelas 
(St. Anthony’s Fire)(2). In response to that injection, some patients showed 
spontaneous remission from their cancers (1). Coley began injecting live and 
weakened bacteria, including Streptococcus pyogenes and Serratia marcescens, 
into the tumours of patients: the first immune-based treatments for cancer (3). 
Despite promising results including long-term survival in some (but certainly not 
all) cancer patients, Coley’s toxins were widely forgotten for over fifty years due 
to the risk of infecting cancer patients with potentially life-threatening bacteria, 
lack of clear understanding of the mechanism of action for these toxins, and the 
rise of radiation-based treatments (with comparatively clear and consistent 
results) at approximately the same time as Coley reported responses to bacterial 




proposing a theory of cancer immunosurveillance (i.e., that lymphocytes act as 
sentinels in recognizing and eliminating continuously arising, nascent 
transformed cells): a role for the immune system in defending against tumour 
initiation and growth (4, 5). However, the enthusiasm for developing 
immunotherapeutic drugs was, thereafter, slow due to limited understanding of 
immune mechanisms and the increase interest in chemotherapeutic approaches. 
Cancer immunosurveillance theory re-emerged in 1974 when more immune cell 
subsets and their function were discovered.  
1.2 Cancer immunosurveillance   
It is clear now that the interaction between the immune system of host organisms 
and cancers arising in, or transplanted into, those host organisms is complex. 
Several studies conducted using mouse models and human samples suggest a 
role for the immune system in cancer formation (6). The immune system not only 
carries out cancer immunosurveillance to eliminate cancer cells but also, 
paradoxically, promotes the growth of poorly immunogenic tumour cells that can 
escape immune surveillance (6, 7). Tumours are composed of a population of 
transformed cells that are morphologically, phenotypically, and genetically 
heterogeneous (8). Because immune cells rely on specific tumour cell antigens 
and susceptibility to innate and humoral immune events to induce death 
(described below), that heterogeneity renders tumour cells variably susceptible to 
immune recognition and attack (9). These immune cells become alerted to the 
stromal remodeling by tumour cells and production of proinflammatory cytokines 




monocytes and natural killer T cells and cytotoxic T cells. The recruited tumour-
infiltrating lymphocytes (TILs) and monocytes eliminate tumour cells by cytotoxic 
mechanisms such as production of interferon gamma (11), in addition to 
production of perforin (12), and pro-inflammatory cytokines such as tumour 
necrosis factor (TNF) (13) which modulate cells in the tumour and was shown to 
exert portent anti-tumour effect through inducing tumour cell cycle arrest, 
apoptosis and necroptosis (14). However, these cytotoxic mechanisms result in 
identification and killing of some, but not all, transformed cells that comprise 
tumour. 
 Tumour cells that escape the early stage of immunosurveillance can then 
be recognized by immune cells (T lymphocytes) that secrete IFN-γ to eliminate 
escaping tumour cells. Although many tumour cells that escaped immune-cell 
elimination are destroyed during this phase, some non-immunogenic tumour 
cells and cells that are well-recognized by immune cells and antibodies but are 
resistant to the mechanisms that induce death survive this stage (15). This stage 
can last for many years and can result in a heterogeneous parental population 
that is highly capable of escaping the immune system. There are several 
mechanisms, selected for tumour cells in this stage which undergoing continuous 
exposure to immune cells and immune cell products, contribute to increasing 
tumour cell immune resistance. These include production of tumour-driven 
soluble factors such as vascular endothelial growth factor (VEGF) and Fas and 
Fas ligand which are produced by many cell types including tumour cells (16, 17) 




resistance (20). In addition, inhibitory signaling molecules such as PD-L1 (21) 
and CTLA-4 (22) and the presence of inhibitory immune cells such as myeloid-
derived-suppressor cells (MDSCs) (23) and T regulatory (Treg) cells (24) can 
suppress T cell effector function. Our understanding of cancer 
immunosurveillance has led to identification of mechanisms by which cancer 
cells can escape immune recognition and elimination (25) and therapeutic 
approaches to prevent tumour cell escape from immune-mediated killing. Those 
therapeutic approaches are described below. 
1.3 Current and developing immunotherapy strategies 
1.3.1 Current immunotherapy strategies 
Tumours with abundant T cell infiltration (“inflamed” tumours), unlike “T-cell 
desert” tumours (characterized by the absence of immune cells) or “T-cell 
excluded” tumours (with peripheral invasion of T cells around tumours but poor 
infiltration into tumours), are a good prognostic biomarker (26). However, the 
presence of T cells within tumours is not sufficient, in itself, to lead to tumour 
regression or elimination. Tumour cells can have multiple characteristics that 
lead to lack of T cell activity, including high levels of immune checkpoint 
molecules that inhibit T cell activation. These molecules are expressed by 
several immune cells including T cells and, after binding to their ligands, can 
induce inhibitory signaling in immune cells (27). Although immune checkpoint 
molecules are necessary to ameliorate and “fine tune” T cell function, their 
activity also reduces their ability to recognize and eliminate tumour cells. 




checkpoint molecules can enhance T cell activation potential and are among the 
most successful immunotherapeutic agents in current clinical use (28). ICBs 
currently used therapeutically antibodies that target T cell immune checkpoint 
molecules and have exhibited good results in enhancing overall survival in 
cancer patients. The first ICB to show a clinical benefit was the anti-CTLA-4 
antibody Ipilimumab in patients with metastatic melanoma (29, 30), non-small-
cell lung cancer (31), small-cell lung cancer (32), renal cell carcinoma (33), and 
prostate cancer (34). Following anti-CTLA-4 blockade, further evidence showed 
clinical benefit in response to treatment with antibodies nivolumab and 
pembrolizumab (35, 36) that target programmed death-1 (PD-1), and antibodies 
durvalumab, atezolizumab and avelumab (37) targeting its ligand PD-L1 (38). 
The use of these monoclonal antibodies to target immune checkpoints has been 
tested and approved in different cancers including advanced melanoma (39, 40), 
non-small cell lung cancer (41), and Hodgkin lymphoma (42), improving overall 
survival in metastatic settings (43). However, these drugs benefit only a minority 
of patients (44). Additional studies are required and under way to investigate 
treatment of other tumour types with ICBs, and the capacity of combining 
blockers with other treatment modalities for additive and/or synergistic 
therapeutic effectiveness.  
         Another current immunotherapeutic approached is the use of adoptive T 
cell (ATC) therapy which was first proposed in 1966 after demonstration that half 
the patients with advanced cancer exhibited tumour suppression after patient-




TILs (46) which can be obtained from excised tumours and expanded in vitro 
before infusion back into the patients, or by obtaining peripheral blood 
lymphocytes that can be engineered to express tumour-specific receptor prior to 
expansion and infusion back to patients (47). The use of TILs was first reported 
in the late 1980s when lymphocytes isolated from a tumour biopsy and then 
expanded in vitro in the presence of IL-2 to generate large numbers of tumour-
reactive lymphocytes were then reinfused back to the same patient, with 
continued in vivo treatment with IL-2 to maintain TIL survival in the body. The 
response rate of this treatment was 34% with a medium time of 4 months (48). 
Although this approach yielded promising results, there were challenges in 
recovering and expanding lymphocytes in vitro. Response to these challenges 
led to development of TCR-engineered lymphocytes and, later, synthetic 
chimeric antigen receptors (CARs) genetically engineered to recognize tumour-
specific or tumour-associated antigens presented by MHC molecules on antigen-
presenting cells, including tumour cells. T cell receptor-engineered T cells are 
prepared from lymphocytes isolated from cancer patients, genetically engineered 
to express chimeric antigen receptors (CARs), and then infused back to the 
same patients. CARs contain an antigen-binding domain associated with the 
signaling domain of the TCR and various co-stimulatory molecules such as CD28 
and CD40 which increase T cell activity in vivo (49, 50).  
 Cancer vaccines are another immunotherapeutic approach used in the 
clinic to enhance the immune system and stimulate anticancer immunity. They 




oncogenic viruses; Gardasil, targeting human papillomavirus subtypes is one 
such preventable vaccine (51)) or “therapeutic vaccines” aimed at activating 
immune cells to eliminate tumour cells (52). Bacillus Calmette–Guérin is an 
example of a vaccine to prevent tuberculosis that can also be used as 
therapeutic vaccine for bladder cancer (53), and sipuleucel (Provenge), a 
vaccine composed of activated antigen-presenting dendritic cells, is approved for 
use in treatment of advanced metastatic prostate cancer (54). Other anti-cancer 
vaccines for use in combination with agents targeting immune checkpoints (anti-
CTLA-4 antibodies, for example) have been explored in the preclinical setting to 
treat melanoma (55) but haves not yet received FDA or Health Canada approval 
for standard treatment of human patients. 
1.3.2 Developing immunotherapy strategies  
Scientists are also investigating newly-discovered strategies to enhance anti-
tumour immunity. Following the clinical success of blockade of immune 
checkpoint blockade molecules (PD-1 and CTLA-4), therapeutic targeting of 
additional negative regulators of T cell activation is under investigation: candidate 
targets for therapeutic suppression include the lymphocyte activation gene 3 
(LAG3), T cell immunoglobulin 3 (TIM3) and T cell immunoreceptor with 
immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains 
(TIGIT)(56). LAG3 is an inhibitory ligand that binds to CD4 and blocks its binding 
to MHC class II molecules (57). Similar to PD-1, LAG3 is a marker for T cell 
exhaustion and can induce cell cycle arrest (57). Although monotherapy with an 




trials, 50% of patients with metastatic breast cancer responded to combination of 
LAG3 blockade and paclitaxel (58). Another negative regulator of the T cell 
response is TIM3: unlike LAG3, it regulates apoptosis following galectin 9 binding 
(59). Increased levels of TIM3 correlated with poor prognosis in non-small-cell 
lung cancer, suggesting a role for it in cancer progression (60). Furthermore, 
increased TIM3 could mediate resistance to anti-PD-1 blockade (61), making it a 
candidate for combination with anti-PD1 therapy. Lastly, TIGIT, which inhibits T 
cell hyperactivation, is highly expressed in TILs compared to peripheral 
lymphocytes. Therapeutic targeting of TIGIT has shown promising results in 
enhancing the effect of pre-existing checkpoint blockade and reversing T cell 
exhaustion (62). So far, the blockade of immune checkpoints other than PD-1 
and CTLA-4 has not shown promising results as single agents but rather as 
adjuvant cancer drugs to increase the effectiveness of other treatments (63).  
 Immune suppression by inhibitory immune cells such as MDSCs can 
contribute to escape of cancer cells from immune detection and elimination. It 
has become clear that some immune checkpoint inhibitor-resistant immune cells 
can successfully respond to immunotherapeutic approaches when combined with 
elimination of immune-suppressor cells (64). MDSCs are among the main 
immune-suppressor cells and have been shown to suppress anti-tumour T cell 
immunity through several mechanisms, including production of arginase, reactive 
oxygen species, IL-10, and sequestration of cystine which is an essential amino 
acid for T cell activation (65, 66). There are a broad range of strategies that can 




which are in pre-clinical trials but have not yet received FDA or Health Canada 
approval. For example, treatment with some chemotherapeutic drugs reduces 
intratumoural and splenic MDSCs (67). In vivo administration of gemcitabine into 
immunologically-competent mice bearing syngeneic large tumour homografts 
derived from five cancer lines grown in both C57Bl/6 and BALB/c mice resulted 
in reduction in the total number of MDSCs in the spleen (68). This elimination 
reduced tumour growth after treatment with immunotherapy (68). The depletion 
of cells was specific to MDSCs as the number of T cell and B cells in spleen was 
not changed in these mice (68). The exact mechanism of this specificity is not 
well understood, but it is possible that because gemcitabine reduced tumour 
growth, it similarly reduced the number of tumour-induced MDSCs. Other 
chemotherapeutic drugs (doxorubicin (69) and 5-FU (70)) administered to 
syngeneic tumour-bearing mice resulted in a similar selective reduction in splenic 
and tumour MDSCs. This strategy and others such as use of a small-molecule 
inhibitor of CXCR1 and CXCR2 and the use of histone deacetylase inhibitors (71, 
72) are under investigation to enhance understanding of MDSC function and 
assess the capacity of drug-induced MDSC cell reduction to treat cancer and 
enhance anti-tumour immunotherapy. 
1.3.3 Increasing T-cell receptor affinity 
Cytotoxic CD8+T cells recognize tumour-associated antigens (TAAs) through 
their T cell receptors (TCRs) which bind to small antigenic epitopes presented by 
the major histocompatibility complex (MHC) class I molecules on the surface of 




T cell activation depends on the affinity of TAAs (bound to MHC Class I or Class 
II molecules) for the TCR, with TCR-MHC interaction stabilising the interaction: 
stronger interactions lead to superior T cell activation and high responsiveness to 
tumour antigens (74) (Figure 1). Induction of effective anti-tumour T cell immunity 
can be increased by enhancing TCR affinity and consequent ability to bind and 
recognize TAAs presented by MHC molecules. On the other hand, to avoid 
hyper-activation and pathological inflammation, T cells have the ability to reduce 
their antigen recognition and responsiveness through molecular mechanisms 
including interaction of the TCR with associated inhibitory molecules (75): 
Increased levels and activity of these molecules results in low anti-tumour T cell 
immunity, as they play a key role in TCR-mediated signaling (75). One example 
of these molecules is CD5, which can regulate TCR signaling (76). CD5 function 
in anti-tumour immunity is the focus of my thesis: current understanding of CD5 

















Figure 1. Antigen presenting cell interaction with CD4+T cell or CD8+ T cell. 
(A) Structure of MHC-II binding to TCR on CD4+ T cells. (B) Structure of MHC-I 










1.4 CD5  
CD5 was first discovered in the late 1960s and was known as Lyt-1, Ly-A 
or Ly-1 (mouse), T1 or Leu-1 (human) (77) until its official name was assigned 
during the first International Workshop and Conference on Human Leukocyte 
Differentiation Antigens (HLDA) in the early 1980s (78). It was initially used as a 
cell surface marker for lymphocytes and to distinguish subpopulations of T and B 
cells (79, 80). It was not until the 1990s, after the first successful cloning of CD5 
genes (81, 82) when more functional studies were performed to increase 
understanding of CD5 structure and function in T and B cells (83, 84) (Figure 2). 
CD5 is a 67 kDa type-I transmembrane glycoprotein and a member of the highly 
conserved group B scavenger receptor cysteine-rich (SRCR) protein superfamily 
(85). It contains three SRCR domains, protein modules of 90 -110 amino acids 
each (86). This superfamily includes more than 30 soluble or membrane-bound 
receptors including CD6, each with at least one SRCR extracellular domain in 
common, and some shown to regulate innate and adaptive responses (87) and 
to play a role in pathogen-associated molecular pattern (PAMP) recognition (88).  
         CD5 is associated with the antigen-specific receptor complex in both T and 
B cells (89-91) and is expressed on both αβ and γδ of T cells (92). It is detectable 
at early stage T cell development (the “double negative” when the TCR is 
present but CD8 and CD4 are not) and its expression increases during 
development from double negative to single positive (CD4+/CD8- or CD8+/CD4-) 
stages (76). It has shown to fine-tune positive and negative selection and 




CD5 has been linked to the strength of T cell receptor signaling (89). It has also 
been reported to be expressed on multiple subsets of immune cells such as 
monocytes (including macrophages (93)) and dendritic cells (94). It is increased 
in regulatory T and B cells (95, 96). Furthermore, T and B cells exposed to 
chronic stimulation are characterize by increased levels of CD5 (97, 98). 
Ligands for CD5 were hard to identify due to the susceptibility of CD5 to 
denaturation and loss during experimental isolation. However, by using soluble 
CD5 purified at neutral pH to stabilize biological activity, CD5 has been shown to 
facilitate species-specific homophilic interactions and that CD5 is a ligand for 
itself (99). Further, the B cell surface protein CD72 in human or Lyb-2 in mice is a 
ligand for CD5 (100). Because CD5 is a member of scavenger receptors which 
play a role in PAMP recognition (101), CD5 can bind to exogenous ligands such 
as β-D-glucan (102) which is a polysaccharide found in the cell walls of yeast 
and mushrooms shown to promote immune response and is anti-tumourigenic  
(103, 104). Evaluation of the role of CD5 role in the T-cell antigen receptor 
signaling pathway has been reviewed previously (105). Here, I review the 
potential therapeutic targeting of CD5 (both depleting or non-depleting 













Figure 2. CD5 Timeline of its discovery and potential use as a therapeutic 











1.5 CD5 in CD5+ non-solid tumours (T and B malignancies) 
1.5.1 CD5 as diagnostic marker for T and B malignancies 
Non-solid tumours (specifically, malignant lymphomas) are neoplasms that arise 
from B or T immune cells during various stages of development (106). Although 
the initial diagnosis of malignant lymphoma is made on the basis of cell 
morphology using histologic or cytologic tests (107), histologically similar 
malignant lymphomas are immunophenotypically and molecularly 
heterogeneous. Immunophenotyping of normal, non-transformed lymphocytes 
can be subdivided based on lineage markers expressed on their cell surfaces. 
For example, T cells express CD2, CD3, CD4, CD5, and CD8 while B cells 
express markers such as CD19, CD20 and CD22. In non-solid B and T cells 
tumours, lineage marker patterns may be similar (108). Hence, the majority of 
non-solid tumours are subdivided according to the pattern of marker expression.  
         CD5 is expressed on T cells and a subset of B cells (B1 cells)(109). CD5 
has been used as characteristic surface marker of T and B cell malignancies. 
Nearly 70% of T-cell malignancies are CD5-positive, including T-cell acute 
lymphoblastic leukaemia (T-ALL) and T-lymphoma (110). CD5 has also been 
used as a useful marker to detect certain B-cell malignancies including B cell 
chronic lymphocytic leukemia (CLL), chronic non-Hodgkin B cell lymphoma 
(NHL), hairy cell leukemia, mantle cell lymphoma (MCL), and small cell 
leukemia/lymphoma (SLL)(111, 112). Approximately 6% of NHL are MCL (113) 




from the mantle zone cells in lymphoid follicles. Furthermore, almost 10% of 
diffuse large B-cell lymphomas (DLBCLs) express CD5 (114). In contrast to CD5, 
other T-cell markers are rarely expressed in B-cell lymphomas, drawing attention 
to CD5 as a diagnostic marker for non-solid tumours. 
1.5.2 CD5 as prognostic marker for T and B cell malignancies  
         CD5 on T and B malignancies vary in amount and is associated with 
clinical outcome and, sometimes, treatment resistance (115). High CD5 levels 
can be correlated with either a positive or negative prognosis, depending on the 
malignancy. Unlike T cell malignancy, CD5 is expressed by a smaller percentage 
of B cell malignancies. The level of CD5 varies among patients with B-CLL (116) 
and high CD5 is associated with better clinical outcome (117). CD5 acts as 
suppressor for B cell receptor (BCR) signaling (118) whereas, upon CD5 
phosphorylation, Src homology-2 protein phosphatase-1 (SHP-1) is recruited to 
the cell membrane resulting in impaired BCR signaling. Because BCR signaling 
is critical for B-CLL tumour cell survival, increased CD5 is associated with better 
clinical outcomes and can be used as prognostic tool for B-CLL patients (119). In 
contrast, high CD5 is correlated with poor prognosis in patients with DLBCL 
(120), the most common subtype of NHL and highly invasive (121). 9.2% of 
DLBCL patients have tumours that express CD5, and this expression was not 
associated with age, sex, or clinical stages but rather with worse clinical 
outcomes (120). These lymphomas exhibit higher BCL-2 and increased 
recurrence in the central nervous system (122). In addition, CD5 has been 




(123). MCL is a disease consisting of several subtypes, most of which are CD5-
positive as they are generated from mantle zone cells in lymphoid follicles (124). 
Mantle cell lymphoma (MCL) patients with a fraction of CD5+ cells less than 80% 
have decreased overall survival compared to those with a fraction higher than 
80% (125). This indicates that favorable prognosis in high CD5+ in MCL is an 
indicator of a favourable prognosis. 
1.5.3 CD5 as therapeutic target on T and B tumour cells  
      Several studies have validated therapeutic targeting of CD5 on T and B 
tumour cells as a therapeutic strategy. Anti-CD5 antibodies conjugated with 
various cytotoxic molecules (ADCs, or antibody-drug conjugates) have been 
used to treat non-solid CD5+ tumours. Anti-human CD5 monoclonal antibody 
(T101) conjugated to the chemotherapeutic drug doxorubicin (DOX) suppresses 
human T-cell leukaemia in athymic mice more effectively than T101 alone or 
DOX alone (126). Selective delivery of immunoconjugates consisting of 
monoclonal antibody T101 targeting CD5 linked to the potent toxin ricin A and 
labeled with radionuclides to the human T lymphoblastoid CEM and MOLT-4 
tumour cell lines expressing CD5 suppressed tumour growth compared to control 
antibody that was minimally inhibitory (127). Killing of CD5+ non-solid tumours 
occurs after diffusion of the potent toxin ricin A through the cell membrane into 
the cytoplasm of the cell to inactivate ribosomes and inhibit protein synthesis to 
induce cell death (128). The use of radiolabeled antibody enhances tumour 
killing at a distance from the binding site and increases the killing directly by 




insensitive to immunoconjugate within the heterogeneous population of 
transformed cells within the tumour (the “bystander” effect). In contrast, CAR-T 
cells exerted a better anti-tumour response against CD5+ tumour cells. In 2015, 
Mamonkin et al. transduced human T cells with chimeric antigen receptor 
targeting CD5 (CD5-CAR-T) to eliminate and kill malignant T cells lines as well 
as primary T-ALL blasts (129). CD5+ CAR-T cells were expanded in vitro and 
were able to target and eliminate CD5+ non-solid malignant T cells and to control 
disease progression in a xenograft mouse model (129). However, there was a 
lack of sustained effect as expansion of anti-CD5 CAR-T cells was transient due 
to cell self-killing (fratricide). 
           Anti-CD5 CAR-T cells have exerted better anti-tumour activity than anti-
CD5 MAbs in directly targeting aggressive T-cell malignancies. However, 
because the majority of T cells express CD5, the treatment approach comes with 
some limitations due to fratricide in the engineered CAR-T cells expressing CD5 
and the off-target toxicity from T-cell aplasia (130). T cell aplasia is a life-
threatening condition resulting in immune system suppression, unlike CAR 
therapy in B cell malignancies which can be managed through intravenous 
infusion of immunoglobulins (131). This problem was resolved by switching to 
two other approaches: CD5-CRISPR-Cas9-edited T cells and CD5-negative NK 
cells (132). The first approach is use of genome-editing CRISPR-Cas9 to knock 
out CD5 in the human Jurkat T cell line. The CD5-edited CD5-CAR-modified 
Jurkat T cells exhibited reduced fratricide and self-activation which can result 




activation when co-cultured with target cells (132). The second approach 
involves use of CD5-negative NK cells engineered to express anti-CD5 CARs. 
An IL-2-dependent NK cell line (NK-92) expressing anti-CD5 CAR effectively 
targeted a CD5+ T cell leukemia cell line in vivo and in vitro (132). However, the 
lack of IL-2 led to low efficacy of the treatment which is essential to maintain NK-
92 proliferation and function. The use of both approaches has potential to 
overcome fratricide in CAR-T cells and enhance the capacity of CAR-T cells to 
therapeutically target CD5 directly on non-solid immune cell malignancies. 
Therapeutic targeting of CD5 on non-tumour cells, on the other hand, has 
potential as a cancer immunotherapy and is described below. 
1.6 CD5 blockade as a therapy to treat CD5- solid tumours  
          The possible immunotherapeutic potential of anti-CD5 MAb in treatment of 
CD5- solid tumours was first reported in the early 1980s (133). Passive 
administration of unconjugated/non-depleting anti-CD5 polyclonal antibody 
reduced tumour growth in mice harbouring non-solid tumour (EL-4 leukemia) and 
solid tumour (Lewis lung carcinoma) (133). This effect was abolished when mice 
were thymectomized, suggesting that the anti-tumour efficacy of anti-CD5 
polyclonal antibody was not directly on the tumour cells but rather on CD5+ 
normal immune cells. Furthermore, genetic knockout of CD5 in mice enhances 
anti-tumour immunity and reduces homograft tumour growth without impairing 
mouse viability: syngeneic mouse B16 melanoma tumours have delayed growth 
in host CD5-/- (knockout) mice (134). Transgenic mice with increased expression 




growth than control mice (135), a phenomenon associated with a reduced 
number of Tregs in lymph node and spleen and an increased number of natural 
killer cells in the spleen. Because soluble CD5 is capable of binding cell surface 
CD5 (99) the authors hypothesized that sCD5 acted to block CD5 from binding 
within the TCR/CD3 complex and impaired the capacity of cell surface CD5 to 
attenuate TCR signaling on T cells (135).  
       The correlation between CD5 level and anti-tumour immunity has been also 
reported in several human studies. TILs isolated from lung cancer patients have 
been reported to exhibit different anti-tumour activity based on CD5 expression, 
where CD5 levels were negatively correlated with anti-tumour activity (136). 
Increased tumour‑mediated activation-induced death (AICD) has been reported 
in T cells with undetectable CD5 levels compared to CD5high T cells, suggesting 
that CD5 could impair activation of anti-tumour T cells (137). This observation 
was associated with increased TIL activation as shown by increased activation 
markers such as CD25 and CD69 (134). However, the delay in tumour growth 
was transit due to increased AICD which can be reverted by blocking pathway 
that induced AICD such as Fas/FasL signaling pathway. Therefore, CD5 may 
negatively regulate T-cell responsiveness to tumour neoantigens and TAAs of 
low immunogenicity and if therapeutically reduced could lead to increased T cell 
recognition and killing of tumour cells expressing such antigenic molecules. As 
such, blocking CD5 signaling could lead to increased anti-tumour immunity and 






1.7 CD5 blockade-mediated immune cell activation  
1.7.1 CD5 on T cells  
       CD5 has been shown to interact with TCR and impair its signaling pathway 
(89). Previous studies have shown that CD5 plays a role in signal transduction 
and participate in phosphorylation of intracellular substrates including protein 
kinase C (138, 139), and enhance intracellular Ca2+ concentration (140). CD5 
has four tyrosine residues (Y378, Y429, Y411, and Y463) in its cytoplasmic 
domain. When tyrosine residues are phosphorylated they recruit several 
molecules and kinases away from the TCR complex, resulting in suppression of 
TCR signaling strength (141). Recruited and excluded molecules include casein 
kinase II (CK2), CBL, SHP-1, PI3K and zeta-chain-associated protein kinase 70 
(ZAP70), which play roles in regulating the TCR signaling pathway (142). SHP1 
inhibits Ca2+ and decrease activation of PLC gamma (142) while ZAP70 
promotes Ca2+ signaling which activates ERK and recruits and activates other 
molecules such as PLC gamma (143). 
       The role of CD5 on the CD3/TCR signaling pathway has an impact on T cell 
function and survival. As previously reported, TILs with low CD5 levels have 
reduced survival: they undergo more AICD as a result of increased activation 
(137). Furthermore, T cells isolated from among TILs and peripheral blood 
lymphocytes from lung cancer patients have been reported to differ in their anti-
tumour effect based on their CD5 levels: higher CD5 levels correlated with lower 




level has an effect on T cell activation threshold (76). CD5 is detectable at very 
early stages of T cell development, and its level increases as T cells progress 
from hematopoietic precursors through to commitment to CD4+ or CD8+ 
expression (76). CD5 is upregulated by engagement of the antigen receptor in 
both immature and mature T cells. These observations support a previously 
study reporting that T cells with genetically-deleted CD5 are hyper-responsive to 
antigen stimulation, a potentially positive characteristic for anti-tumour immunity 
(141). Together, these data support the potential of blocking CD5 to increased 
anti-tumour immunity and enhanced immune cell activation. 
1.7.2 CD5 on B cells 
      CD5 on B cells was first studied in B-CLL until it was shown that CD5 is also 
expressed in other subpopulations of B cells isolated from spleen, lymph nodes, 
and blood (144, 145). Further studies on B cell subpopulation revealed that B1 
cells can be subdivided into two types based on CD5 level (CD5+ B1a cells and 
CD5- B1b cells) (146). Similar to T cells, the physical correlation between CD5 
and BCR suggests a potential functional role that can regulate B cell activation. It 
was reported that CD5 plays a negative role in BCR signaling: CD5-deficient B1 
cells treated with anti-IgM antibodies show increased proliferation (147).  
Furthermore, CD5-deficient B1 cells showed decreased apoptosis and promoted 
NF𝜅B translocation to the nucleus (147). The link between CD5+ B cells and 
tumour immunity has been previously reported. CD5+ B cells lacking IL-6R𝛼 and 
isolated from within tumours was reported to bind IL-6 directly through CD5 




activation of STAT3 (148). Furthermore, CD5+ B cells but not CD5- B cells 
promoted B16 melanoma growth, suggesting that CD5+ B cells might promote 
tumour progression (148). The same year, another study reported that IL-6-
binding to CD5 in B cells promotes tumour growth via JAK-STAT signaling (149). 
         Most studies focus on CD5 as a marker for B malignancies and 
autoimmune diseases, which may not represent the normal physiological 
function of CD5 in untransformed B cells. Hence, the underlining mechanism 
through which CD5 regulates B cell survival and development is still not well 
understood. It has been shown that B cells expressing CD5 produced greater 
amounts of IL-10 compared to B cells lacking CD5 (150). Furthermore, BCR 
stimulation in B cells lacking CD5 are more susceptible to apoptosis compared to 
B cells expressing CD5 (151). These results suggest a regulatory role for CD5 in 
B cell survival. A further study investigated the role of CD5 as a regulator 
molecule for B cell survival using B-CLL cells as a model (152). In this study, 
Daudi B cells transfected with a CD5 expression vector had hyperphosphorylated 
tyrosine residues on CD5 suggesting that CD5 activation in B cells may enhance 
B cell survival in the context of B cell malignancy (152). The exact mechanism 
underling CD5-mediated B cell survival requires further investigation. Several 
studies reported potential involvement of specific signaling pathways: cross-
linking of anti-CD5 in a subset of B-CLL cells induces PKC activation which 
resulted in induction of the Bcl-2 pro-survival family protein known as Mcl-1 




CLL, and suggested that Lyn-mediated SHP-1 recruitment of CD5 could promote 
resistance to apoptosis (115).  
         In contrast to T cells, CD5 expressed in a subset of B cells exhibited a 
proapoptotic function. CD5-deficient B1 cell has been shown improved survival 
compared to wild type B1 cells, suggesting that CD5 may protect them from 
apoptosis. These data are difficult to interpret as CD5-deficient B1 cells 
represent a small fraction of all B cells and their function compared to B1a cells 
is not yet well understood (147). Furthermore, one study reported that CD5 on 
resting B cells could induce apoptosis, as opposed to T cells where it was not 
associated with apoptosis (154). In fact, treatment with anti-CD5 in B-CLL 
induced tumour apoptosis in some patients (155-157). These data suggest that 
CD5 function may have a dual function based on the type of cell; it may be pro-
apoptotic in certain malignancies such as B-CLL but anti-apoptotic in normal B 
and T cells.  
1.7.3 CD5 on dendritic cells 
 Dendritic cells (DCs) are a heterogeneous group of professional APCs 
comprised of conventional DCs (cDCs), including plasmacytoid DCs (pDCs) and 
CD11c myeloid DCs (mDCs)(158). The first study to report CD5-expressing DCs 
was published in 1992, showing that DCs isolated from human peripheral blood 
express CD5 (159). Later, human cDC2 isolated from lymph nodes, skin 
(Langerhans cells), and tonsils have been reported to be sub-dividable based on 
their CD5 level (160-162). Furthermore, in mice the majority of DC subtypes 




CD5 expression has not been reported to affect DC generation and maturation 
but rather to affect their function. The functional relevance of CD5 in DCs is not 
well understood: one published report indicated that CD5+ DCs isolated from 
blood represents a mature phenotype, however their function differ according to 
their CD5 expression (160). CD5high DCs were able to induce proliferation of 
naïve T cells better than CD5low DCs (160). Furthermore, CD5high DCs induced 
increased generation of Tregs (i.e., those expressing IL-10, IL-22, and IL-4) 
whereas CD5low DCs were able to induce increased numbers of IFNγ-producing 
T cells (cytotoxic T cells)(160). It has been reported that CD5-deficient DCs 
produced higher levels of IL-12 compared to wild-type DCs when challenged with 
LPS (163). CD5-deficient DCs were able to induce anti-tumour immunity in mice 
(163). Furthermore, CD5-deficient DCs were capable of inducing higher 
activation of both CD4+ and CD8+ T cells as assessed by increased production of 
IL-2 and IFN-γ (163). These effects were abolished after restoring CD5 
expression to the CD5-deficent DCs, suggesting that CD5 can reduce production 
of pro-inflammatory cytokines in DCs: that reduction can decrease their ability to 
activate T cells and induce strong adaptive immunity. The functional relevance of 
CD5 in DC, therefore, requires further investigation. 
1.8 CD5 in clinical trials 
     Several phase I clinical trials have been conducting using an anti-CD5 
monoclonal antibody. The first was to test the therapeutic effectiveness of a 
monoclonal mouse antibody (T101) directed against CD5 on human patients 




T-cell lymphoma (CTCL) and four with chronic lymphocytic leukemia (164) and 
reported relative specificity and efficacy of monoclonal antibody therapy but the 
clinical benefit was limited. Another study reported testing of T101 in 13 patients 
[eight with CTCL and five with various other T cell malignancies] and reported 
complete remission in one patient with convoluted T cell lymphoma and partial 
remission in one patient with CTCL (165). These studies reported that higher 
doses of the antibody were associated with higher toxicity to the patients and the 
treatment outcome was limited due to antigen modulation as well as 
development of human anti-mouse antibodies resulting in neutralization of 
treatment. Further studies validated immunoconjugated T101 to enhance 
treatment outcome. A phase I clinical trial tested the use of 
radioimmunoconjugate 90Y-T101 in ten patients [eight with cutaneous T-cell 
lymphoma and two with chronic lymphocytic leukemia](166). All patients with 
cutaneous T-cell lymphoma developed human an anti-mouse response after 
finishing one cycle of the infusion and therefore did not receive any further 
infusion. Five of the patients, two with chronic lymphocytic leukemia and three 
with cutaneous T-cell lymphoma, showed partial responses and one patient with 
cutaneous T-cell lymphoma is in complete remission after 6 years (166). The use 
of monoclonal anti-CD5 immunoconjugate with ricin A chain toxin shows some 
limitation in patients due to development of human anti-mouse antibodies (167). 
Some durable limiting toxicities to kidney and liver due to non-specific uptake of 
the toxin conjugate were observed but were not fatal (167). These clinical trials 




of CAR-T cells may be of more clinical value. Work by Mamonkin et al. (129), 
showed the efficacy of CD5+ CAR T cells in targeting CD5+ malignant T cells and 
led to initiation of a phase I clinical trial (NCT03081910) in 2017 with an 
estimated primary completion date of 2021. This clinical trial has been recently 
published a promising result and demonstrate that CD5 CAR T cells are safe 
when administrated in five patients with relapsed or refractory (r/r) non-Hodgkin T 
cell lymphoma (T-NHL) and induce clinical responses without inducing complete 
T-cell aplasia (168). Furthermore, genetic variants of CD5 may affect tumour 
development and could be used as prognostic markers in patients with certain 
tumours. Two studies have shown the effect of two CD5 single nucleotide 
polymorphisms SNPs (rs2241002 and rs2229177) in solid and non-solid tumours 
(169, 170). A study has investigated two cohort of patients with melanoma and 
revealed increased survival in patients with ancestral haplotype (169). Another 
study has reported chronic lymphocytic leukemia patients carrying ancestral 











Table 1: Clinical trials for CD5 in solid and non-solid tumours 
Cancer type Treatment approach Phase Year 
initiated 
Publication 
 Chronic lymphocytic 
leukemia  
 Cutaneous T-cell 
lymphoma 
Monoclonal antibody to 
human T-cell (T101) 
Phase I 1984 (164) 
 Cutaneous T cell 
lymphomas (CTCL) 
 Various other T cell 
malignancies 
Monoclonal antibody to 
human T-cell (T101) 
Phase I 1986 (165) 
 Cutaneous T-cell 
lymphoma  




Phase I 1998 (166) 




Phase I 1991 (167) 







 Chronic lymphocytic 
leukaemia 







 T-cell Acute Lymphoma 
 T-non-Hodgkin 
Lymphoma 
 T-cell Acute Leukemia 





1.9 Mouse models to study cancer immunotherapy drugs 
 The validation of immunotherapeutic drugs efficacy requires the 
availability of reliable mouse models that represent the complexity of immune 
cells interaction within the tumour. Several mouse models have been developed 
to test different aspect of cancer. Herein, I briefly describe the most widely-used 
mouse models employed to assess cancer immunotherapy. 
1.9.1 Humanized tumour models 
 Human xenograft models are among the oldest models used to examine 
the efficacy of cytotoxic drugs to treat cancer by inoculating 
immunocompromised mice such as athymic nude or severe combined 
immunodeficiency (SCID) animals with human tumour cell lines (171). SCID mice 
are deficient in a DNA-dependent protein kinase required for T- and B-cell 
development therefore result in lack in normal thymic development and deficient 
in T-cell function. Although this model lacks T-cell function, innate immune cells 
such as neutrophils and dendritic cells remain present and limit the engraftment 
of human hematopoietic tumour cell lines. Therefore, the use of this model is 
limited in testing cancer immunotherapy drugs. 
1.9.2 Syngeneic tumour models 
 These models are among the first preclinical models used to test anti-
cancer agents. Fully immunocompetent mice (inbred strains such as C57BL/6 
and BALB/c) have been used to validate immuno-oncology agents without the 
need for adoptive transfer of immune cells into host mice. In these models, 




grow tumours either subcutaneously or orthotopically (i.e., at the organ site 
specific to the tumour type). The use of syngeneic tumour cell lines is relatively 
easy compared to other models as it can be rapidly expanded prior to 
implantation into the host and are relatively reproducible in different research 
contexts. Another logistical advantage of using this model is the flexibility in 
selection of model tumour cell lines based on criteria such as poor or good 
immunogenicity, and relative ease of genetic manipulation of tumourigenic cell 
lines prior to implantation (as opposed genetic manipulation of mice to create 
tumour-prone animal lines) to induce expression of antigens of interest to 
examine antigen-specific anti-tumour responses. 
1.9.2.1 The murine 4T1 breast tumour cell line 
 The 4T1 syngeneic mouse tumour cell was first isolated as subpopulation 
410.4 from a mammary tumour arising in BALB/cfC3H mice (172). This is a 
poorly immunogenic tumour model that can metastasize to multiple distant sites 
such as lymph nodes, liver, lung and brain (173). It can grow progressively 
causing lethal disease even after tumour excision (174). There is several 
characteristics that makes 4T1 tumour a suitable experimental animal model to 
validate targeting CD5 in T cells. First, it recapitulates the triple-negative breast 
cancer in human as it metastasizes to the draining lymph nodes and other 
organs (174). Second, it can be easily transplanted into mammary gland as an 
orthotopic tumour. Also, 4T1 tumour cell expresses poorly immunogenic tumour 
antigens which makes it a suitable model to examine the ability of CD8+ T cells to 




1.10 Hypothesis and objectives: 
         Hypothesis: Functional blockade of CD5 on the surface of primary mouse 
cytotoxic T cells will enhance recognition of poorly immunogenic tumour antigens 
and promote T cell activation (Figure 3). 
        Objectives: 
 Objective 1. Characterize CD5 levels in T cell subsets and under different 
activation conditions (quiescence and induced activation). 
 Objective 2. Explore the association of CD5 with T cell activation and 
exhaustion.  
 Objective 3. Target CD5 receptor using CD5-blocking antibodies ex vivo, in 
primary CD8+ T cells isolated from mouse spleen, and assess CD8+ T cell 
activation and function. 
 Objective 4. Evaluate the anti-tumour efficacy of anti-CD5 as single 
treatment in vivo and evaluate T cell function and activation in T cell subsets 
derived from spleen, lymph nodes, and tumours.  
 Objective 5: Evaluate the anti-tumour efficacy of anti-CD5 antibody in 














Figure 3: CD5 blocking and its possible effect during immunological 
synapse. In the immunological synapse in normal T lymphocytes, CD5 
physically interacts with TCR, limiting TCR function and TAA recognition. When 
CD5 is targeted using anti-CD5 MAb, TCR affinity is increased which leads to 
enhanced T cell activation. This figure was generated by me and was selected 
for the “In This Issue” section in the European Journal of Immunology (vol. 50, 







Chapter 2  
1 Materials and methods 
2.1 Table 2: Key resources 
REAGENT or RESOURCE SOURCE CLONE IDENTIFIER 
Antibodies (For in vivo administration) 
Anti-CD5 Mouse IgG2a, Fc 






InVivoMAb anti-mouse PD-1 
(CD279), IgG2a 
Bio X cell RMP1-
14 
BE0146 
Anti-Fluorescein Mouse IgG2a, 




4-4-20  Ab00102-2.3 
Antibodies (For in vitro administration) 
Purified NA/LE Hamster Anti-














Purified NA/LE Hamster Anti-
Mouse CD28  
BD 
Biosciences 
37.51  553294 
Ultra-LEAF™ Purified anti-mouse 
CD28  
BioLegend 37.51 102116 
Purified anti-mouse CD5  BioLegend 53-7.3 100602 









R35-95  553927 
Antibodies (For flow cytometry) 
Brilliant Violet 711™ anti-mouse 
CD3  
BioLegend 17A2 100241 
Alexa Fluor® 700 anti-mouse 
CD4  
BioLegend GK1.5 100430 
PE/Cyanine7 anti-mouse CD5  BioLegend 53-7.3 100622 
FITC Rat Anti-Mouse CD5 BD 
Biosciences 
53-7.3 553020 





PE-Cy™7 Rat Anti-Mouse CD8a  BD 
Biosciences 
53-6.7   552877 
Brilliant Violet 605™ anti-mouse 
CD25  
BioLegend PC61 102036 
PE Hamster Anti-Mouse CD69 BD 
Biosciences 
H1.2F3 561932 





Brilliant Violet 421™ anti-mouse 
CD107a (LAMP-1)  
BioLegend 1D4B 121618 
PE anti-mouse CD137  BioLegend 17B5 106106 







PE anti-mouse CD152 (CTLA-4) BioLegend UC10-
4B9 
106306 
PE anti-mouse CD178 (FasL)  BioLegend MFL3 106606 




CD279 (PD-1)  2 
PE/Dazzle™ 594 anti-
mouse/human CD11b  
BioLegend M1/70 101256 





PE anti-mouse IFN-γ  BioLegend XMG1.2 505808 
Purified anti-mouse CD16/32 (For 
Fc block) 
BioLegend  93 101302 
Alexa Fluor® 488 anti-
mouse/rat/human FOXP3  
BioLegend 150D 320012 
Isotype antibodies (for flow cytometry) 





PE Armenian Hamster IgG 
Isotype Control Antibody 
BioLegend HTK888 400908 









Isotype Control Biosciences 







Antibodies (For western blot)  













Anti-mouse horse radish 
peroxidase antibody conjugate 
Cell Signaling  7076S 
Anti-rabbit horse radish 
peroxidase antibody conjugate 
Cell Signaling  7074S 
Recombinant Proteins and Media for Cell Culture  









Medium (DMEM) Aldrich 
Fetal Bovine Serum (FBS) Invitrogen 12483020 
Recombinant Human IL-2 Peprotech 200-02 
Other reagents 
Propidium iodide BioLegend 421301 
FITC Annexin V BioLegend 640906 
Annexin V Binding Buffer BioLegend 422201 
Zombie NIR™ Fixable Viability Kit BioLegend 423106 
MojoSort™ Magnet BioLegend 480019 
MojoSort™ Buffer (5X) BioLegend 480017 
MojoSort™ Mouse CD8 T Cell 
Isolation Kit 
BioLegend 480008 
Fixation Buffer BioLegend 420801 
Brefeldin A Solution (1,000X) BioLegend 420601 
Intracellular Staining 






Female BALB/c mice The Jackson 
Laboratories 
000651 









CFSE Cell Division Tracker Kit  BioLegend 423801 


















BD™ LSR II Flow Cytometer BD 
Biosciences 
n/a 










Semi-dry transfer apparatus Bio-Rad n/a 
Software  
Prism, version 8  Graphpad https://www.graphpad.com/ 
Flowjo, version 10 FlowJo, LLC https://www.flowjo.com/ 
      2.2 Experimental model and subject details 
      2.2.1 Mice  
          Female BALB/c mice were purchased from The Jackson Laboratories 
(Jackson Laboratories, Bar Harbor, ME). All animals were between 8 and 12 
weeks of age and housed in the Animal Care and Veterinary Services Facility at 




guidelines of the Canadian Council for Animal Care and under the supervision of 
the Animal Use Subcommittee of the University of Western Ontario. 
2.2.2 Cell lines  
            4T1 mouse breast mouse tumour cells were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA), and cultured in 
Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum 
(FBS)(Invitrogen). All cells were kept at 37°C in 5% CO2.  
2.2.3 Syngeneic mouse tumour model 
           4T1 tumour cells were counted by Coulter counter and resuspended into 
sterile PBS at a concentration of 5×105 cells/ml. One hundred microliters of cells 
(5X104) were injected subcutaneously into the right flanks of 2-month-old female 
BALB/c mice and allowed to grow until 21 days before animals were euthanized 
by CO2 inhalation for immune cell assessment. For tumour growth assessment, 
the tumour growth was measured by caliper and the largest length and width 
dimensions were used to calculate tumour volumes and mice were euthanized 
once tumour size reach endpoint at 1500 mm3. 
2.2.4 In vivo drug treatment  
         Four different treatment protocols were used to study the effect of CD5 




First treatment design  
         This experiment was design to test the impact of anti-CD5 MAb to reduce 
tumour growth as a single agent and in combination with anti-PD-1 MAb. Mice 
were injected subcutaneously with 4T1 tumour cells and as soon as tumours 
reached 50 mm3 (day 7), mice were divided into 4 different groups and were 
administered one of the following treatments on days 7, 10, 13, and 16: isotype 
control MAb alone, anti-CD5 MAb alone, anti-PD-1 MAb alone, or a combination 
of both anti-CD5 + anti-PD-1 MAbs. Mice received their treatments by i.p 
injection of 200 μg of each agent/mouse (Figure 4).  
 
Figure 4. Scheme of the first in vivo treatment design  
 




         This experiment was designed to assess the less dosage of anti-CD5 MAb 
in reducing tumour growth as a single agent or in combination with anti-PD-1 
MAb. Mice were injected subcutaneously with 4T1 tumour and cells as soon as 
tumours reached 50 mm3 (day 7), mice were divided into 4 different groups and 
received one of the following treatments: isotype control MAb alone (200 μg) (day 
7), anti-CD5 MAb alone (200 μg) (day 7), anti-PD-1 MAb alone (200 μg) (days 
10, 13, and 16), or a combination of anti-CD5 MAb (day 7) + anti-PD-1 MAb 
(days 10, 13, and 16) (Figure 5).  
 







Third treatment design  
        This experiment is design to assess whether anti-CD5 can enhance efficacy 
of chemotherapy gemcitabine to suppress tumour growth.  Mice were injected 
subcutaneously with 4T1 tumour cells and as soon as tumours reached 50 mm3 
(day 7), mice were divided into 4 different groups and received one of the 
following treatments: PBS (day 7 and 10), gemcitabine alone (day 7), anti-CD5 
MAb alone (day 10), or a combination of gemcitabine (day 7) + anti-CD5 MAb 
(day 10). Mice received only one treatment of 100 μg anti-CD5 MAb/mouse one 
treatment of 60 mg/kg gemcitabine (Figure 6).  
 







Fourth experiment design  
          This experiment is design to assess whether anti-CD5 can enhance 
efficacy of chemotherapy 5-FU to suppress tumour growth. Mice were injected 
subcutaneously with 4T1 tumour cells and as soon as tumours reached 50 mm3 
(day 7), mice were divided into 4 different groups and received one of the 
following treatments: PBS (day 7, 10 and 14), anti-CD5 MAb alone (days 7, 10, 
and 14), 5-FU alone (day 7), or both anti-CD5 MAb (days 7, 10, and 14) + 5-FU 
(day 7). The 5-FU dose was 50 mg/kg and the anti-CD5 MAb doses were 50 









Fifth experiment design  
          This experiment is designed to assess whether anti-CD5 MAb has the 
capacity to suppress tumour growth when administered at lower dosage, and in 
treatment of a smaller number of injected tumour cells, than described in the 
"Fourth in vivo treatment design". Mice were injected subcutaneously with 5000 
4T1 tumour cells and, as soon as tumours reached 50 mm3 (day 7), mice were 
divided into two different groups and received one of the following treatments: 
isotype control on day 0 and every three to four days of a total of 11 injections 
and anti-CD5 MAb alone (on day 0 and every three to four days of a total of 11 
injections. The isotype control and the anti-CD5 MAb doses were 25 μg/mouse 
each (Figure 8). 
 
Figure 8. Scheme of the fifth in vivo treatment design. 
2.3 Methods 




          Single cell suspensions of lymphocytes were obtained from mice by 
pressing spleens or lymph nodes through a 70 μm Falcon Cell Strainer (VWR, 
Mississauga, ON) into RPMI 1640 medium (GIBCO). Cells were then centrifuged 
(300xg, 10 mins, 4°C), and erythrocytes were lysed using Ammonium-Chloride-
Potassium (ACK) red cell lysis buffer. The resulting live (trypan blue-negative) 
splenocytes and lymphocytes were counted manually (microscope slide) and 
stained directly or cultured for further assessment. 
2.3.2 Tumour-infiltrating lymphocyte (TIL) preparation 
         TILs were obtained from freshly-resected tumours, which were isolated 
immediately after euthanization of mice. Tumours were cut into 2-3 mm3 
fragments and each tumour was placed into individual wells of a 6 well plates 
and incubated in 2 ml of an enzyme digest mix consisting of RPMI1640 complete 
media containing 15% fetal bovine serum (FBS)(Invitrogen) and 
10 mg/ml collagenase A (Sigma-Aldrich Canada, Oakville, ONT) and incubated 
for 2 hours at room temperature under continuous rotation. 
2.3.3 4T1 mouse breast tumour lysate preparation  
           4T1 tumour lysate was prepared by detaching confluent cultures of 4T1 
tumour cells with 0.01% EDTA for 10 min, washing the cells twice with PBS, 
resuspending cells in serum-free medium (5X106 cells/ml), and lysis by 5 
freeze/thaw cycles (-80 to 37°C) accomplished by repetitive 5 min on dry ice 




protein concentrations were then determined using a Bradford assay following 
the manufacturer’s recommended protocol.  
2.3.4 Western immunoblotting 
 Splenocytes were stimulated for 30 min with 2 μg/ml anti-CD3 MAb 
(Clone: 145-2C11. BD Biosciences) or 2 μg/ml anti-CD3 + 5 μg/ml anti-CD5 
MAbs (Clone: 53-7.3. BioLegend) to induce activation of T lymphocyes. After 
stimulation, cells were washed twice with cold PBS and lysed with RIPA lysis 
buffer (10 mM Tris pH 7.2, 2mM  EDTA, 0.1% SDS, 1% sodium deoxycholate, 
1% Triton 100), supplemented with protease inhibitors, including 10 μg/ml 
aprotinin, 10 μg/ml leupeptin, 100 μM sodium orthovanadate, 100 μM 
phenylmethylsulfonyl fluoride, and sonicated at 4ºC using a Vibra CellTM 
ultrasonic processor (Sonics & Materials Inc., Danbury, CT) to disrupt 
membranes. Lysates were centrifuged at 13,000 × g for 15 min at 4ºC. Protein 
concentration was measured using the Bradford assay. For SDS PAGE, 30 μg 
protein per lane was electrophoresed on a 7% polyacrylamide gel and proteins 
were then transferred to a nitrocellulose membrane using a semi-dry transfer 
apparatus (Bio-Rad) and blocked with 5% skim milk in TBST for 1 hour. 
Membranes were incubated overnight with the primary antibody at 4ºC. After 
washing three times in TBST, membranes were incubated with the appropriate 
secondary antibody-horse radish peroxidase conjugate for 1 hour at 21o C and 
proteins were then detected by using enhanced chemiluminescence reagents 
(Western Lightning Plus – ECL [Perkin Elmer, Inc Products]). Primary antibodies 




Biolabs, Whitby, ON) and anti-actin (Sigma Aldrich Canada, Oakville, ON). Anti-
mouse or anti-rabbit horse radish peroxidase antibody conjugates were 
purchased from Cell Signaling. 
2.3.5 In vitro activation  
         Single cell suspensions of splenocytes were generated from naïve mice 
using the protocol described in section 2.3.1 and in accord with MIATA 
guidelines. On day 0, cells (2X105) were treated with or without purified anti-
mouse anti-CD5 MAb at 5 µg/ml (Clone: 53-7.3. BioLegend) for 15 min before 
seeding into U-bottom 96-well plates pre-coated with 5 µg/ml anti-CD3 antibody, 
in RPMI media containing 10% FBS, IL-2 (50 IU/ml)(PeproTech Canada Inc), 
and soluble anti-CD28 antibody (Clone: 37.51. BD Biosciences, 2 µg/ml). Media 
was replaced every 48 hours with a fresh RPMI media containing 10% FBS, IL-2 
(50 IU/ml) were kept at 37°C in 5% CO2 for the period of experiment.  
2.3.6 Ex vivo activation  
           Single cell suspensions of splenocytes were generated from 4T1-
harbouring mice using the protocol described in section 2.3.1 and in accord with 
MIATA guidelines. Cells (2X105) were reactivated by addition of 4T1 tumour cell 
lysate (200 µg/well) in a 96-well plate treated with or without purified anti-mouse 
anti-CD5 MAb at 5 µg/ml (Clone: 53-7.3. BioLegend), in RPMI media containing 
10% FBS and IL-2 (50 IU/ml)(PeproTech Canada Inc). Cultured splenocytes, 
activated and unactivated, were kept at 37°C in 5% CO2 and the media 




2.3.7 T cell apoptosis  
 On day 7 of the in vitro and ex vivo activation, apoptotic and dead cell 
fractions were determined using a FITC‑labeled Annexin‑V and propidium iodide 
(PI) kit (Biolegend, San Diego, CA) according to the manufacturer’s protocol. 
Briefly, cells were stained with anti-mouse PE-Cy7‑labeled anti-CD8 MAb at 4°C 
for 30 min, washed twice with cold FACS buffer, and resuspended in Annexin V 
staining buffer (Biolegend, San Diego, CA). FITC-Annexin V (1 μg/ml) and PI (10 
μg/ml) were added to the cell suspension and incubated at 21°C for 15 min in the 
dark. Annexin V staining buffer (400 μl) was added and cells were analyzed 
using a Cytomics FC 500 (Beckman Coulter, Inc). 
2.3.8 T cell proliferation 
           For CFSE labelling, isolated splenocytes were stained with CFSE (1 
μg/ml; Biolegend, San Diego, CA) for 15 min at 37°C and washed twice with 
FBS-containing buffer to stop the reaction. Cells were then cultured as described 
in section 2.3.5 and 2.3.6 for 7 days at 37°C in 5% CO2, followed by flow 
cytometry using a Cytomics FC 500 flow cytometer (Beckman Coulter, Inc). Data 
were analyzed using Flowjo software (BD Bioscience).  
2.3.9 Flow cytometry  
 To assess the levels of surface protein expression, the antibodies 
described in Table 2 (Key Resources) were used for flow cytometry. Flow 




BD™ LSR II Flow Cytometer and data analyzed using Flowjo software (BD 
Bioscience). To assess the level of the indicated markers, spleens, lymph nodes 
and TILs were collected from either tumour-naïve mice or tumour-bearing mice 
21 days after tumour cell injection. Cells were prepared as previously described, 
and 2X105 cells were treated with purified anti-mouse CD16/32 antibody (Clone 
93)(Biolegend, San Diego, CA) for 15 min at 21°C in the dark to block 
CD16/CD32 interactions with the Fc domain of immunoglobulins. Cells were then 
stained with appropriate antibodies for 25 mins on ice in the dark, washed twice 
with FACS staining buffer, suspended in 0.5 ml FACS staining buffer, and 
analyzed by flow cytometry. The European Journal of Immunology Guidelines for 
the use of flow cytometry and cell sorting in immunological studies (175) were 
followed. 
2.3.10 Intracellular cytokine staining (ICS) 
 To measure IFNγ in CD8+ T cells, ICS was restricted to detection of IFNγ 
(a cytokine produced by CD8+ cells upon activation (176)). Splenocytes from 
either tumour-naïve or 4T1 tumour-bearing BALB/c mice were isolated and single 
cell suspensions prepared as described. Splenocytes from tumour-naïve mice 
(2X105) were treated as described above. For splenocytes obtained from tumour-
bearing mice, 4T1 tumour lysate was added to re-stimulate the cells, with or 
without addition of function-blocking anti-CD5 MAb. Cells were incubated at 37°C 
overnight. Brefeldin A (10 μg/ml) was added to retain secretion of IFNγ in the 
Golgi apparatus. After 3 hours cells were stained with anti-mouse FITC-CD8a 




ice and incubated in the dark for 30 min. The samples were washed twice and 
fixed in 2% paraformaldehyde (50 μl). To detect CD8+ T cell activation, samples 
were stained for 30 min with PE-conjugated anti-mouse IFNγ (1 μg/ml in 
intracellular staining permeabilization wash buffer) (Biolegend, San Diego, CA). 
Samples were then washed and harvested in FACS buffer for flow cytometry. 
Flow cytometric data were analyzed using Flowjo software (BD Bioscience).  
2.3.11 Ex vivo cytotoxic T lymphocyte (CTL) assay  
 4T1 cells were stained with CFSE cell tracking dye (green) and plated in 
glass-bottomed 96-well plates (5X103 cells/well) in triplicate. After cells adhered 
to the plate for 2 hours, CD8+ T cells isolated from spleens of tumour-bearing 
mice using a MojoSort™ Mouse CD8 T Cell Isolation Kit (Biolegend, San Diego, 
CA) were treated with isotype control or anti-CD5 MAb and added into each well 
at a 1:1 ratio with a final well volume of 200 μl. Propidium iodide was added to 
wells to detect dead cells. Images were taken every 2 hours, and the cytotoxic 
capacity of CD8+ T cells was measured using an IncuCyte Zoom live cell imaging 
system (Essen BioScience, Ann Arbor, MI) by counting yellow objects using 
metric phase object confluence (propidium iodide [red] binding to dead CFSE+ 
4T1 cells [green]). 
2.3.12 CD8+ T cell purification  
            MojoSort™ Mouse CD8 T Cell Isolation Kit (BioLegend, San Diego, CA) 
were used for magnet-based cell separation of CD8+ T cells. The protocol was 




T cells were depleted by incubating splenocytes with the biotin antibody cocktail 
followed by incubation with magnetic streptavidin nanobeads. The untouched 
CD8+ T cells were collected by decanting the liquid in a clean tube and the 
magnetically labeled fraction was retained using a magnetic separator. 
2.3.13 Cell counting 
 4T1 tumour cells were grown for 3 days before harvesting for an 
experiment, washed with PBS, trypsinized and counted on a Beckman Coulter 
Z1 Particle Counter (Beckman, Mississauga, Ontario, Canada). Results were 
analyzed by calculating the average number and multiple by 80 as the following  




 Splenocytes and lymphocytes were isolation from mice and prepared for 
single cell suspension. The resulting cells were stained with trypan blue to 
distinguish dead cells from live cells and counted manually on microscope slides. 
Cell numbers were calculated using the following equation: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 =
𝐴 + 𝐵
2
𝑋 2 𝑋 10   
2.3.14 Statistical analysis   
 Statistical differences were assessed using a Student's unpaired one-
tailed t-test (GraphPad Prism 8.2.1) to test the relationship between independent 
variables. No comparisons were made between dependent variables (that is, 
groups defined by segregation on the basis of one variable before making 




rather than ANOVA analysis. One-tailed analysis was employed in preference to 
two-tailed to analysis because only the capacity of experimental treatments to 
alter response of cells or tumours in one direction (increased or decreased levels 
of relevant measures) was of interest. Unpaired rather than paired testing was 
conducted because test subjects (mice and cells) were independent of each 
other (that is, not the same test subjects prior to and after treatments). Data 
points indicate means of n values ± standard deviation (SD). Differences 
between data sets where p ≤ 0.05 were considered to be significant. Asterisks 






Chapter 3  
CD8+ T tumour-infiltrating lymphocytes with downregulated cell surface 
expression of CD5 exhibited an increased level of activation and 
exhaustion 
3.1 Preamble 
 CD5, a member of the scavenger receptor cysteine-rich superfamily, is a 
marker for T cells and a subset of B cells (B1a). CD5 associates with T-cell and 
B-cell receptors and increased CD5 is an indication of B cell activation. In 
tumour-infiltrating lymphocytes (TILs) isolated from lung cancer patients, CD5 
levels were negatively correlated with anti-tumour activity and tumour‑mediated 
activation-induced T cell death, suggesting that CD5 could impair activation of 
anti-tumour T cells. I determined CD5 levels in T cell subsets in different organs 
in mice bearing syngeneic 4T1 breast tumour homografts and assessed the 
relationship between CD5 and increased CD69 and PD-1 (markers of T cell 
activation and exhaustion) by flow cytometry. I report that T cell CD5 levels were 
higher in CD4+ T cells than in CD8+ T cells in 4T1 tumour-bearing mice, and that 
high CD5 levels on CD4+ T cells were maintained in peripheral organs (spleen 
and lymph nodes). However, both CD4+ and CD8+ T cells recruited to tumours 
had reduced CD5 compared to CD4+ and CD8+ T cells in peripheral organs. In 
addition, CD5highCD4+ T cells and CD5highCD8+ T cells from peripheral organs 
exhibited higher levels of activation and associated exhaustion compared to 




CD8+ T cells among TILs and downregulated CD5 were activated to a higher 
level, with concomitantly increased exhaustion markers, than CD8+CD5+ TILs. 
Thus, differential CD5 levels among T cells in tumours and lymphoid organs can 
be associated with different levels of T cell activation and exhaustion, suggesting 
that CD5 may be a therapeutic target for immunotherapeutic activation in cancer 
therapy. 
3.2 Results  
3.2.1 Differential CD5 expression among organs and T cell subsets 
         CD5 is expressed on the majority of T cells (76). However, differences in 
the levels of expression among T cell subsets isolated from different peripheral 
organs are not well-described. To determine the level of CD5 among T cell 
subsets and within peripheral organs and tumour cells, mice subcutaneously 
implanted with syngeneic triple-negative 4T1 breast tumours were euthanized on 
day 21 after implantation and spleen, lymph nodes, and tumour tissue were 
harvested and processed to generate single cell suspensions containing immune 
cells. The recovered cells were stained for CD5 and surface markers of T cell 
subsets and analyzed by flow cytometry. The results show that CD4+ T cells in 
spleen and lymph nodes had higher levels of surface CD5 than CD8+ T cells in 
those tissues (Figure 9A). There was no significant difference between CD5 
levels in CD4+ T cells from spleen and lymph nodes (Figure 9B), and no 
significant difference in CD5 levels between CD8+ T cells from spleen and lymph 
nodes (Figure 9C). Interestingly, both CD4+ and CD8+ T cells infiltrated into 




lymph nodes and spleen (Figures 9B, 9C). Taken together, these data indicate 
that CD5 levels are significantly higher in CD4+ T cells compared to CD8+ T 
cells. Furthermore, a fraction of both CD4+ T cell and CD8+ T cells recruited to 
the tumour have lower CD5 levels than T cells in lymph and spleen, either 
because CD5 is downregulated by the tumour or T cells with lower CD5 are 



























Figure 9: CD5 levels in T cell subsets and lymphoid organs. T cells isolated 
from 4T1-harbouring BALB/c mice were stained with fluorescence-conjugated 
anti-CD3, anti-CD4, anti-CD8, and anti-CD5 MAbs. (A) CD5 levels on CD8+ T 
cells and CD4+ T cells in lymph nodes and spleen. (B) The fraction of CD5+CD4+ 
T cell isolated from the lymph nodes, spleen and TILs. (C) The fraction of 
CD5+CD8+ T cells isolated from the lymph nodes, spleen, and TILs. Data are 
shown as means ± SD of 3 mice per group and from one representative 
experiment of three independent experiments. FMO: Fluorescence Minus One 
Control. TILs: tumour-infiltrating lymphocytes. MFI: mean fluorescence intensity. 









3.2.2 CD5 level on CD4+ and CD8+ T cells is induced upon TCR/CD3 
stimulation       To determine if CD5 levels on T cells are affected by the 
presence of tumour homografts, T cells were isolated from lymph nodes of naïve 
mice and 4T1-harbouring mice on day 21 after tumour cell implantation. Cells 
were stained with anti-CD5 MAb in addition to antibodies targeting CD3, CD4, 
and CD8. The levels of CD5 on the surfaces of naïve T cell and T cell from 4T1 
tumour homograft-harbouring mice showed different patterns of expression. CD5 
levels on both CD4+ T cells (Figure 10A) and CD8+ T cells (Figure 10B) were 
significantly higher in lymph nodes of mice harbouring 4T1 tumours than in 
tumour-naïve mice. Furthermore, as previously reported by us, CD5 levels on 
CD8+ T cell splenocytes were significantly increased after TCR/CD3 stimulation 
by ex vivo treatment with anti-CD3/anti-CD28 MAbs compared to non-stimulated 
CD8+ T splenocytes (Figure 10C)(177). Together, these results reveal that the 
presence of tumour homografts in mice leads to elevated CD5 on T cells in 
lymph nodes, similar to the increase in CD5 seen after ex vivo stimulation of the 










Figure 10: CD5 expression by CD4+ and CD8+ T cells is increased upon 
activation. Lymphocytes isolated from naïve mice or 4T1 tumour-harbouring-
BALB/c mice were stained with MAbs targeting CD4, CD8, and CD5. (A) The 
level of CD5 on CD4+ T cells isolated from lymph nodes of naïve mice and 4T1 
tumour-harbouring mice. (B) The level of CD5 expression on CD8+ T cell isolated 
from lymph nodes of naïve mice and 4T1 tumour-harbouring mice. (C) 
Splenocytes isolated from naive BALB/c mice were treated with anti-CD3/anti-
CD28 MAb on day 0 and cells were quantified by flow cytometry after 24 h for 
CD5 level on CD8+ T cells. Data are shown as means ± SD of 3 mice per group 
and from one representative experiment of three independent experiments. FMO: 
Fluorescence Minus One Control. MFI: mean fluorescence intensity. *p < 0.05 










3.2.3 CD5high T cells in spleen and lymph nodes exhibit increased activation 
        The increased level of CD5 on T cells upon TCR/CD3 stimulation suggests 
that CD5 level may be directly increased by that activation. To address how CD5 
levels may be associated with T cell activation, a gating strategy was applied to 
determine the activation level of CD5high T cells and CD5low T cells based on the 
level of the T cell activation marker CD69 (178)(gating strategy described in 
Figure 11C). Mice were challenged by subcutaneous injection of 4T1 tumour 
cells 21 days prior to euthanasia, at which time lymph nodes and spleens were 
collected. T cells isolated from those organs were stained with anti-CD69 and 
anti-CD5 MAbs in addition to antibodies against T cell markers (anti-CD3/anti-
CD8/anti-CD4 MAbs). The results show that the fraction of CD69+CD5highCD4+ T 
cells in spleen and lymph nodes was significantly higher than the fraction of 
CD69+CD5lowCD4+ T cells (Figure 11A). Similarly, the fraction of 
CD69+CD5highCD8+ T cells was significantly higher than the fraction of 
CD69+CD5lowCD8+ T cells in spleen and lymph nodes (Figure 11B). Collectively, 
these data suggest a correlation between CD5 level and T cell activation in 
































Figure 11: The correlation of CD5 with CD69 on CD4+ and CD8+ T cells. 
Lymphocytes isolated from 4T1-harbouring BALB/c mice were stained with 
fluorescence-conjugated anti-CD3, anti-CD4, anti-CD8 and anti-CD5 MAbs. (A) 
The fraction of CD69+CD5highCD4+ T cell and CD69+CD5lowCD4+ T cell in spleen 
and lymph nodes. (B) The fraction of CD69+CD5highCD8+ T cell and 
CD69+CD5lowCD8+ T cell in spleen and lymph nodes. (C) Gating strategy. Data 
are shown as means ± SD of 5 mice per group and from one representative 















3.2.4 CD5-/low T cells display increased activation in the tumour  
       T cells recruited to the tumour have reduced CD5 levels compared to T cells 
in lymph nodes and spleens. To determine the level of activation of CD5+ and 
CD5-/low tumour-infiltrating T cells, the level of the activation marker CD69 in both 
CD4+ and CD8+ T cell subpopulations in T cells isolated from 4T1 tumours 
excised from mice at 21 days following subcutaneous implantation of tumour 
cells was determined. The data show that the fraction of CD69+CD5-/low CD4+ T 
cells from tumours was significantly higher than the fraction of CD69+CD5+CD4+ 
T cells (Figure 12A). Similarly, the fraction of CD69+CD5-/lowCD8+ T cells was 
significantly higher than the fraction of CD69+CD5+CD8+ T cells (Figure 12B). 
This suggests that the fraction of CD4+ and CD8+ TILs with reduced CD5 levels 
in the tumour have higher levels of activation compared to CD5+CD4+ and 
























Figure 12. The fraction of CD5high and CD5-/low tumour-infiltrating 
lymphocytes (TILs) expressing CD69. TILs isolated from 4T1-harbouring-
BALB/c mice were stained with fluorescence-conjugated anti-CD3, anti-CD4, 
anti-CD8, anti-CD5 and anti-CD69 MAbs. (A) The fraction of CD69+CD5highCD4+ 
T cell and CD69+CD5-/lowCD4+ T cell in TILs. (B) The fraction of 
CD69+CD5highCD8+ T cell and CD69+CD5-/lowCD8+ T cell in TILs. Data are shown 
as means ± SD of 4 mice per group and from one representative experiment of 












3.2.5 CD5high T cells in spleen and lymph nodes exhibit increased 
exhaustion 
       Upon activation, T cells express high levels of CD5. T cells can also up-
regulate exhaustion/activation markers such as PD-1 upon activation (179). To 
determine whether CD5highT cells exhibit a higher exhaustion phenotype 
compared to CD5low T cells, T cells from spleen and lymph nodes of 4T1 tumour-
harbouring mice were isolated on day 21 following subcutaneous implantation of 
the tumour cells. Recovered cells from spleen and lymph nodes were then 
stained with anti-PD-1 and anti-CD5 MAbs in addition to T cell panel markers 
(anti-CD3/anti-CD8/anti-CD4 MAbs) and analyzed by flow cytometry. The results 
show that the fraction of PD-1+CD5highCD4+ T cell was substantially higher than 
the fraction of CD69+CD5lowCD4+ T cells in spleens and lymph nodes (Figure 
13A). Similarly, the fraction of PD-1+CD5highCD8+ T cells was significantly higher 
than the fraction of PD-1+CD5lowCD8+ T cells in spleen and lymph nodes (Figure 
13B). Collectively, these data suggest that elevated CD5 levels on T cells is 






















Figure 13: The correlation of CD5 level with PD-1 level in CD4+ and CD8+ T 
cells from spleen and lymph nodes of tumour-bearing mice. Lymphocytes 
isolated from 4T1-harbouring-BALB/c mice were stained with fluorescence-
conjugated anti-CD3, anti-CD4, anti-CD8, anti-CD5 and anti-PD-1 MAbs. (A) The 
fraction of PD-1+CD5highCD4+ T cell and PD-1+CD5lowCD4+ T cell in spleen and 
lymph nodes. (B) The fraction of PD-1+CD5highCD8+ T cell and PD-1+CD5lowCD8+ 
T cell in spleen and lymph nodes. Data are shown as means ± SD of 3 mice per 
group and from one representative experiment from three independent 










3.2.6 CD5-/lowCD8+T cells display increased exhaustion in the tumour  
        Downregulation of CD5 level was associated with an increased fraction of 
activated CD4+ and CD8+ T cells in the tumour. To determine the exhaustion 
level in CD5-/lowCD4+ vs CD5+CD4+ TILs and in CD5-/lowCD8+ vs CD5+CD8+ TILs, 
TILs were stained with anti-PD-1 MAb and with antibodies to detect CD5, CD4, 
CD8 and CD3 and analyzed by flow cytometry. The results show a significantly 
elevated fraction of PD-1+CD5-/lowCD8+ TILs compared to PD-1+CD5+CD8+ TILs 
(Figure 14B). Interestingly, this was the opposite of what was observed in CD4+ 
TILs, where the fraction of PD-1+CD5-CD4+ TILs was significantly lower than PD-
1+CD5+CD4+ TILs (Figure 14A). These data suggest that, the fraction of CD5-/low 
CD8+ TILs become exhausted in the tumour compared to CD5+CD8+ TIL but not 






















Figure 14. CD5-/lowCD8+ T cells from tumour-bearing mice exhibit an 
exhaustion phenotype compared to CD5+CD8+ T cells. TILs isolated from 
4T1-harbouring-BALB/c mice were stained with fluorescence-conjugated anti-
CD3, anti-CD4, anti-CD8, anti-CD5 and anti-PD-1 MAbs. (A) The fraction of PD-
1+CD5highCD4+ T cell and PD-1+CD5-/lowCD4+ T cell in TILs. (B) The fraction of 
PD-1+CD5highCD8+ T cell and PD-1+CD5-/lowCD8+ T cell in TILs. Data are shown 
as means ± SD of 3 mice per group and from one representative experiment of 















CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell 
cytotoxicity 
4.1 Preamble:  
 CD5 is a therapeutically-targetable tumour antigen expressed on leukemic 
T and B cells. However, the potential therapeutic effect of blocking CD5 function 
to increase T cell anti-tumour activity against tumours other than leukemia 
(including solid tumours) has not been explored. CD5 knockout mice show 
increased anti-tumour immunity and reduced homograft tumour growth: reducing 
CD5 on CTLs may be therapeutically beneficial to enhance the anti-tumour 
response. Here I show that ex vivo administration of a blocking anti-CD5 
monoclonal antibody (MAb) to primary mouse CTLs isolated from spleens of both 
naive mice and mice bearing mouse 4T1 breast tumour homografts enhances 
their capacity to respond to activation by treatment with anti-CD3/anti-CD28 
MAbs or 4T1 tumour cell lysates. Furthermore, ex vivo CD5 blocking MAb 
treatment reduced CD5 signaling (erk activation) and increased markers of 
spleen T cell activation including proliferation, CD69 levels, interferon-γ 
production, apoptosis, and Fas receptor and Fas ligand levels. Finally, CD5 
blocking MAb treatment enhanced the capacity of primary mouse spleen CD8+ T 
cells to kill 4T1 mouse tumour cells in an ex vivo assay. These data support the 






4.2.1 CD5 blockade enhances CD8+ T cell receptor signaling 
Increased phosphorylation of Erk is a downstream effect of activating TCR 
signaling pathway (180). Erk2 regulates CD8+ T cell proliferation and survival 
(181). A previous report showed elevated Erk phosphorylation in the absence of 
CD5-CK2 signaling (182). To determine if using anti-CD5 MAb could lead to 
impaired CD5 signaling pathway and increased Erk activation. I treated naïve 
splenocytes with anti-CD3 MAb alone or anti-CD3 and anti-CD5 MAbs and 
showed increased phosphorylation of Erk1/2 in cells receiving anti-CD3 and anti-
CD5 MAbs using western blot (Figure 15A and B). Furthermore, treatment with 



































Figure 15. Increased ERK phosphorylation in anti-CD3/anti-CD5 MAb-
treated splenocytes. Splenocytes isolated from naive BALB/c mice were treated 
with anti-CD3 MAb or with anti-CD3 and anti-CD5 MAbs for 30 min and then cells 
were lysed and phosphorylation of Erk was detected by western blot. (A) The 
level of ERK phosphorylation was normalized to loading control actin. (B) 
Membrane immunoblotted for p-ERK and actin from cells treated with nothing, 
anti-CD3 and anti-CD3/anti-CD5. (C) Membrane immunoblotted for p-ERK and 
actin from cells treated with anti-CD5, anti-CD3 and anti-CD3/anti-CD5. Data are 
mean ± SD (n = 3 mice), one representative experiment of three. *p < 0.05 










4.2.2 CD5 blockade enhances CD8+ T cell activation and proliferation 
 CD5-/- T cells exhibit increased levels of T cell activation markers (CD25, 
CD69) after treatment with anti-CD3 MAb (183). To determine whether blocking 
CD5 function using an anti-CD5 MAb, in combination with activation by anti-CD3 
MAb/anti-CD28 MAb, would enhance CD8+ T cell activation, I treated primary 
splenocytes isolated from tumour-naive mice with anti-CD3/anti-CD28 MAbs and 
anti-CD5 MAb for 24 hours in vitro and then assessed the level of the activation 
marker CD69 on CD8+ T cells among those splenocytes. Cells treated with anti-
CD3/anti-CD28 MAbs in addition to anti-CD5 MAb showed an increased fraction 
of CD69+CD8+ T cells compared to cells received anti-CD3/anti-CD28 MAbs and 
isotype control MAb (82% vs 78% respectively, p < 0.05)(Figure 16A; for the 
gating strategy Figure 16B). To further assess CD8+ T cell activation upon 
treatment with anti-CD5 MAb, proliferation of CD8+ T cells was examined. 
Splenocytes from either tumour-naïve mice or mouse 4T1 tumour-bearing mice 
were stained with CFSE cell tracking dye and treated with anti-CD3/anti-CD28 
MAbs or 4T1 tumour lysate, in addition to anti-CD5 MAb or isotype control MAb. 
CD8+ T cells treated with anti-CD5 MAb exhibited increased proliferation 
compared to those treated with isotype control MAb up to 5 divisions with almost 
20% cells in each division with anti-CD3/anti-CD28 MAbs and up to 5 divisions 
with 4T1 tumour lysate with almost 20% cells in division 3 and less than 10% 
cells in division 4 and 5. The increase percentage of cells in each divisions was 






















Figure 16. CD8+ T cell activation after treatment with anti-CD5 MAb 
blockade. (A) Quantification of fraction of CD69+CD8+ T cells. (B) Gating 
strategy for splenocytes isolated from naive BALB/c mice were treated with anti-
CD3/anti-CD28 MAb with or without anti-CD5 MAb (day 0), CD69+CD8+ cells 
were quantified by flow cytometry 24 h later using PE anti-mouse CD69. Data are 
mean ± SD (n = 3 mice), one representative experiment of two. *p < 0.05 

























Figure 17. CD8+ T cell proliferation after treatment with anti-CD5 MAb 
blockade. (A) Splenocytes isolated from naive BALB/c mice were stained with 
cell tracking dye (CFSE) then activated with anti-CD3/anti-CD28 MAb, with or 
without anti-CD5 MAb (day 0). (B) Splenocytes from mouse 4T1 breast tumour 
harbouring BALB/c mice were stained with cell tracking dye (CFSE) and then 
were treated with 4T1 lysate with or without anti-CD5 MAb (day 0). Cells were 
incubated for 7 days and media were replaced every 48 h. CFSE dye levels were 
quantified by flow cytometry: increased dilution of dye indicated increased CD8+ 
T cell proliferation (A and B). Data are mean ± SD (n = 3 mice), one 











4.2.3 Increased fraction of CD8+ IFNγ+ T cells after treatment with anti-CD5 
MAb 
  IFNγ is an effector cytokine produced by activated CD8+ T cells (176). To 
determine whether treatment with anti-CD5 MAb enhances production of IFNγ in 
CD8+ T cells, splenocytes from either naïve mice or mouse 4T1 tumour-bearing 
mice were stimulated for 24 h in vitro with anti-CD3/anti-CD28 MAbs or 4T1 
tumour lysate, respectively, in addition to anti-CD5 MAb or isotype control MAb. 
The fraction of cells positive for IFNγ after treatment with both anti-CD3/anti-
CD28 MAbs and anti-CD5 MAb was greater than the fraction after treatment with 
anti-CD3/anti-CD28 MAbs and isotype control MAb, 18% vs 21% respectively p < 
0.05 (Figure 18A). The MFI was higher in cells treated with both anti-CD3/anti-
CD28 MAbs and anti-CD5 MAb treatment 3 x103 vs 5 x 103 respectively p < 0.05 
indicating that not only was fraction of IFNγ+ cells increased, but the level of IFNγ 
in those cells was also higher (Figure 18A and B). The fraction of CD8+ T cells 
from 4T1 tumour-bearing mice treated ex vivo with tumour lysate in addition to 
anti-CD5 MAb also had an increased fraction of IFNγ+ T cells from 0.6% to 1.5%, 
p < 0.05 (Figure 19A and B). Furthermore, to assess if blocking CD5 has a direct 
affect on CD8+ T cells, I purified CD8+ T cells from the whole splenocytes and 
then treat the cells with anti-CD3/anti-CD28 MAbs with or without ani-CD5 MAb. 
After 24 hours, the cells treated with addition of anti-CD5 MAb has greater 






















Figure 18. Increased fraction of CD8+ IFN-γ+ T cell after treatment with anti-
CD5 MAb. Splenocytes isolated from naive BALB/c mice were treated with anti-
CD3/anti-CD28 MAb with or without anti-CD5 MAb (day 0). (A) Quantification of 
the fraction of CD8+ IFN-γ+ T cell and the MFI of IFN-γ. (B) Gating strategy. Data 
are mean ± SD (n = 3mice), one representative experiment of three, *p < 0.05, 

























Figure 19. Increased fraction of CD8+IFN-γ+ T cells after treatment with anti-
CD5 MAb ex vivo. Splenocytes from mouse 4T1 breast tumour-harbouring 
BALB/c mice were treated with 4T1 lysate with or without anti-CD5 MAb (day 0). 
(A) Quantification of the fraction of CD8+ IFN-γ+ T cell and the MFI of IFN-γ. (B) 
Gating strategy. Data are mean ± SD (n = 3 mice), one representative 


























Figure 20: IFNγ in purified CD8+ T cells following activation, with or without 
anti-CD5 MAb blockade. (A) Gating strategy for purified CD8+ T cells after 
activation with or without anti-CD5 MAb (B) Quantified data. CD8+ T cells positive 
for IFNγ+ were quantified by flow cytometry 24 hours later. Gating was based on 
the size of splenocytes, then gated on CD8+ cells and then on IFNγ and CD8. 
Data are mean ± SD (n=3 mice), *p < 0.05 (Student's unpaired one-tailed t-test), 














4.2.4 CD5 blockade increases FasR- and FasL-dependent death of CD8+ T 
cells 
 CD5 may decrease TCR tumour antigen recognition, and CD5 blockade 
could enhance antigen recognition and intracellular TCR signaling. A 
consequence of repeated antigen stimulation of the CD3/TCR complex is 
activation-induced cell death (AICD)(20, 184). To assess whether anti-CD5 MAb 
could increase CD8+ T cell death after activation as a consequence of enhanced 
TCR sensitivity to antigen, splenocytes from tumour-naive mice were treated with 
anti-CD3/anti-CD28 MAbs, with or without anti-CD5 MAb, on day 0. Cells were 
cultured as previously described with media refreshed every 48 hours. On day 7 
cells were stained with anti-CD8 MAb followed by staining with FITC-annexin V 
and PI (Figure 21A and B for gating strategy). The fraction of CD8+ T cells 
undergoing AICD (Annexin V+/PI+) was increased among those activated with 
anti-CD3/anti-CD28 MAbs and anti-CD5 MAb, compared to those treated with 
anti-CD3/anti-CD28 MAbs and isotype control MAb: 78% vs 60%, p < 0.05. For 
splenocytes from 4T1 tumour-bearing mice, treatment with anti-CD5 MAb 
enhanced AICD compared to treatment with isotype control MAb: 59% vs 40%, p 
< 0.05 (Figure 22A and B for gating strategy). AICD has been shown to depend 
on FasR/FasL interaction (185): consequently, I assessed the fraction of FasR+ 
CD8+ and FasL+ CD8+ T cells. Splenocytes from tumour-naïve mice and mouse 
4T1 tumour-bearing mice were isolated and treated with anti-CD3/anti-CD28 
MAbs or 4T1 lysate, respectively, with or without anti-CD5 MAb. Cells obtained 




fluorescent antibodies and analyzed by flow cytometry to detect FasR and FasL 
on CD8+ T cells. Splenocytes treated with anti-CD3/anti-CD28 MAbs in addition 
to anti-CD5 MAb had an elevated fraction of FasR+CD8+ T cells compared to the 
isotype control MAb-treated group at 48, 72, and 96 hours after activation 40% vs 
30%, 50% vs 39% and 78% vs 50% respectively with p < 0.05 (Figure 23A and B 
for gating strategy). In addition, the level of FasR in FasR+ cells was increased 
after anti-CD5 MAb treatment compared to isotype control MAb-treated group at 
48 hours 1.3 x 103 vs 1.2 x 103 and at 96 hours 1.6 x 103 vs 1.3 x 103 
respectively with p < 0.05 (Figure 23A and B for gating strategy). The fraction of 
FasL+CD8+ T cells was also increased in cells treated with anti-CD5 MAb at 72 
hours 60% vs 30% and at 96 hours 80% vs 60% respectively with p < 0.05 
(Figure 23A and B). Similarly, the fraction of FasR+CD8+ T cells among mouse 
4T1 tumour-bearing splenocytes treated with anti-CD5 MAb was increased 
compared to cells treated with isotype control MAb, at 48 and 72 hours after 
activation 45% vs 35% and 40% vs 35% respectively with p < 0.05; the fraction of 
FasL+CD8+ T cells treated with anti-CD5 MAb was increased compared to cells 
treated with isotype control MAb at 96 hours 65% vs 60% respectively with p < 
0.05 (Figure 24A and B for gating strategy); and the level of FasR on FasR+CD8+ 
T cells was higher at 96 hours after anti-CD5 treatment compared to isotype 




















Figure 21. Increased CD8+ T cell apoptosis after activation with anti-
CD3/anti-CD28 antibodies and treatment with anti-CD5 MAb. Splenocytes 
from naive, non-tumour bearing BALB/c mice were activated with anti-CD3/anti-
CD28 MAb, with or without anti-CD5 MAb. Cell viability was assessed by flow 
cytometry on day 7 (cells positive for Annexin V only were deemed to be 
undergoing early apoptosis; for both Annexin V and PI labelled as late 
apoptosis).  (A) Quantified data (B) Gating strategy. Data are mean ± SD (n = 3 
mice), one representative experiment of two, *p < 0.05, ns, not significant 























Figure 22. Increased CD8+ T cell apoptosis after activation with 4T1 tumour 
cell lysate and treatment with anti-CD5 MAb. Splenocytes from mice 
harbouring 4T1 breast tumours were treated with 4T1 lysate, with or without anti-
CD5 MAb. Cell viability was assessed by flow cytometry on day 7 (cells positive 
for Annexin V only were deemed to be undergoing early apoptosis; for both 
Annexin V and PI labelled as late apoptosis). (A) Quantified data (B) Gating 
strategy. Data are mean ± SD (n = 3 mice), one representative experiment of 






















Figure 23. Increased fractions of FasR+CD8+ and FasL+CD8+ T cells after 
stimulation with anti-CD3/anti-CD28 MAbs and treatment with anti-CD5 MAb 
ex vivo. Splenocytes from naive, non-tumour bearing BALB/c mice were treated 
on day 0 with anti-CD3/anti-CD28 MAb with or without anti-CD5 MAb. CD8+ T 
cells were quantified by flow cytometry every 24 h for FasR and FasL positivity. 
(A) Quantified data. (B) Gating strategy. Data are mean ± SD (n = 3 mice), one 
representative experiment of three, *p < 0.05 (Student’s unpaired one-tailed t-
























Figure 24. Increased fractions of FasR+CD8+ and FasL+CD8+ T cells after 
stimulation with 4T1 tumour cell lysate and treatment with anti-CD5 MAb ex 
vivo. Splenocytes from BALB/c mice harbouring 4T1 breast tumours were 
treated with 4T1 lysate, with or without anti-CD5 MAb (day 0). CD8+ T cells were 
quantified by flow cytometry every 24 h for FasR and FasL positivity. (A) 
Quantified data. (B) Gating strategy. Data are mean ± SD (n = 3 mice), one 
representative experiment of three, *p < 0.05 (Student’s unpaired one-tailed t-












4.2.5 CD5 blockade enhances tumour killing by CD8+ T cells 
 To determine if treatment of CD8+ T cells with anti-CD5 MAb could 
enhance T cell-mediated cytotoxicity against tumour cells, I assessed ex vivo 
killing of mouse 4T1 tumour cells by primary CD8+ T cells isolated from mice and 
treated with blocking anti-CD5 MAb. Mice were challenged with 4T1 tumour cells 
for 21 days and CD8+ T cells were isolated and co-cultured with 4T1 cells in vitro 
in combination with ex vivo treatment with anti-CD5 MAb. Two-dimensional cell 
cultures containing T cells and 4T1 cells were maintained in an IncuCyte live cell 
analysis system to captured live image to detect the ability of CD8+ T cells to kill 
and lyse tumour cells. CD8+ T cells treated with anti-CD5 were more capable in 
killing tumour cells compared to cells received isotype control or received 
nothing. At 6 and 10 hours post treatment there were more than 30 dead 
cells/mm3 with cells received anti-CD5 blockade compared to less than 20 dead 




























Figure 25. Anti-CD5 MAb enhances ex vivo CD8+ T cell-mediated killing of 
mouse 4T1 breast tumour cells. Cytotoxic CD8+ T cells were isolated from 
BALB/c mice bearing mouse 4T1 breast tumours, treated with the isotype control 
MAb or anti-CD5 MAb or control (nothing) and mixed with CFSE-stained 4T1 
cells in vitro at a 1:1 ratio. PI was added to measure cell death and an 
IncuCyteR_S3 Live-Cell Analysis System was used to image the cells every 2 h. 
Yellow objects which represent CFSE stained 4T1 (green) binding to PI (red) 
were counted as a measure of 4T1 tumour cell death. Data are mean ± SD (n = 3 









Chapter 5  
Administration of anti-CD5 MAb in vivo enhances CD8+ T cell activation and 
function in a poorly immunogenic 4T1 breast tumour model 
5.1 Preamble 
 CD5 is a characteristic surface tumour marker for T and B cell 
malignancies. The therapeutic potential of depletion of non-solid CD5+ tumour 
cells has been explored using anti-CD5 depleting antibodies and CD5 CAR T 
cells. In solid CD5- tumour cells, CD5 knockout mice exhibit increased anti-
tumour immunity (134). This suggests that blocking CD5 function may have a 
therapeutic effect by enhancing cytotoxic T lymphocyte activity. The effect of 
administering an anti-CD5 antibody to block CD5 function and enhance T cell 
activation and function in vivo has not been explored. Here I injected 
immunocompetent mice with poorly immunogenic, triple-negative mouse 4T1 
breast tumour cells and tested whether administration of anti-CD5 MAb in vivo 
could enhance normal T cell activation and effector function. The data show that 
administration of anti-CD5 MAb increased the ration of CD8+ T/CD4+ T cells in 
draining lymph nodes and within tumours. In addition, I observed significantly 
increased activation and effector function of T cells isolated from spleen, draining 
lymph nodes, and tumours. Furthermore, the fraction of exhausted T cells was 
significantly enhanced after administration of effector-blocking anti-CD5 MAb. 




enhance immune activation in response to poorly immunogenic antigens, either 
alone or in combination with other drugs including immunotherapeutic drugs. 
5.2 Results 
5.2.1 Anti-CD5 MAb treatment increases the fraction of CD8+ T cells relative 
to CD4+ T cells in tumours and draining lymph nodes     
            Increased CD8+ T cells relative to CD4+ T cells in tumours correlate with 
better progression-free survival in breast cancer patients (186). I determined 
whether the administration of an anti-CD5 MAb in vivo affected the ratio of 
CD8+/CD4+ T cell ratio in spleen, draining lymph nodes, and within tumours. As 
assessed by flow cytometry, there was a higher fraction of CD8+ T cells and a 
lower fraction of CD4+ T cells among all CD3+ cells (i.e., T lymphocytes) in 
draining lymph nodes and among tumour-infiltrating lymphocytes (TILs) after 
treatment with anti-CD5 MAb (Figure 26A). However, treatment with anti-CD5 
MAb did not induce a similar increase the fraction of CD8+ T cells and decrease 
in the fraction of CD4+ T cells in spleens (Figure 26A). These results were further 
confirmed in analysis of CD8+/CD4+ T cell ratios (Figure 26B). As expected, there 
was a significant increase in the ratio of CD8+/CD4+ T cells in draining lymph 
nodes and TILs, but not in spleens of mice treated with anti-CD5 MAb compared 
to those treated with isotype control MAb (Figure 26B). These data suggested 
that treatment with anti-CD5 MAb enhances CD8+ T cell fractions within tumours 
























Figure 26. Fraction of CD8+ T and CD4+ T cells after treatment with anti-CD5 
MAb in vivo. (A) CD8+ T and CD4+ T cells from spleen, draining lymph node, 
and TILs isolated from 4T1 tumour-bearing BALB/c mice treated with anti-CD5 
MAb or isotype control MAb. (B) CD8+/CD4+ T cell ratios calculated from spleen, 
draining lymph node, and TILs. Data are mean ± SD (n = 3 mice), one 
representative experiment of three, ns, not significant, *p < 0.05 (Student’s 













5.2.2 Increased CD8+ T cell activation after treatment with anti-CD5 MAb in 
vivo  
        In a published study I show that splenocytes stimulated ex vivo with anti-
CD3/anti-CD28 MAbs or 4T1 tumour lysate and treated with anti-CD5 MAb had 
an increased fraction of CD8+CD69+ T cells compared to cells stimulated with 
anti-CD3/anti-CD28 or 4T1 tumour lysate and isotype control (177). To 
investigate whether in vivo administration of anti-CD5 MAb enhanced T cell 
activation, I excised spleens, draining lymph nodes, and 4T1 tumours from mice 
and assessed the levels of CD69 (a marker of T cell activation) on T cells in 
those organs. The results show an increase in the fraction of CD69+CD4+ T 
cells in spleens and draining lymph nodes in anti-CD5 MAb-treated mice (Figure 
27A). Furthermore, I assessed the levels of CD69 on CD4+ T cells and I found 
the mean fluorescence intensity of CD69 was higher in CD4+ TILs in anti-CD5 
MAb-treated mice (Figure 27A). Furthermore, I found increased fraction 
of CD69+CD8+ T cells in spleen and draining lymph nodes of mice treated with 
anti-CD5 MAb compared to isotype control MAb-treated mice (Figure 27B). 
Furthermore, similar to CD4+ TILs, CD8+ TILs isolated from anti-CD5 MAb-
treated mice had a higher level of CD69 compared to isotype control MAb-treated 
mice (Figure 27B). These data indicate that treatment with anti-CD5 MAb 












Figure 27. Fraction of CD8+CD69+ T and CD4+CD69+ T cells after treatment 
with anti-CD5 MAb in vivo. (A) The fraction of CD4+CD69+ T and MFI of CD69 
on CD4+ T cells isolated from spleens, draining lymph nodes, and TILs excised 
from 4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb or 
isotype control MAb. (B) The fraction of CD8+CD69+ T cells and MFI of CD69 on 
CD8+ T cells isolated from spleens, draining lymph nodes, and TILs isolated from 
4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb or isotype 
control MAb. Data are mean ± SD (n = 3 mice), one representative experiment of 
three, ns, not significant, *p < 0.05 (Student’s unpaired one-tailed t-test), MFI: 




5.2.3 Increased CD8+ T cell exhaustion after treatment with anti-CD5 MAb in 
vivo 
 PD-1 is a co-inhibitory receptor that is highly expressed on exhausted T 
cell (187). It can also indicate chronic stimulation of T cells and is an indication of 
activation (179). The expression of the T cell exhaustion marker PD-1 
was assessed on T cells following treatment with anti-CD5 MAb in vivo. The data 
show that mice treated with anti-CD5 MAb had a higher fraction of PD-1+CD4+ T 
cells in spleen, draining lymph nodes, and within 4T1 tumours compared to mice 
treated with isotype control MAb (Figure 28A). The MFI of PD-1 was also higher 
in anti-CD5 MAb-treated CD4+ T cells isolated from spleens, draining lymph 
nodes, and tumours (Figure 28A). Furthermore, treatment with anti-CD5 MAb 
increased the fraction of PD-1+CD8+T cells and MFI of PD-1 in spleens and 
draining lymph nodes (Figure 28B). No significant difference in the fraction of PD-
1+CD8+T cells or PD-1 level was observed in CD8+ TILs (Figure 28B) after 















Figure 28. The fraction of CD8+PD-1+ T and CD4+PD-1+ T cells after 
treatment with anti-CD5 MAb in vivo. (A) The fraction of CD4+PD-1+ T cells 
and the MFI (mean fluorescence intensity) of PD-1 on CD4+ T cells isolated from 
spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing 
BALB/c mice that were treated with anti-CD5 MAb or isotype control MAb. (B) 
The fraction of CD8+PD-1+ T cells and MFI of PD-1 on CD8+ T cells isolated from 
spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing 
BALB/c mice that were treated with anti-CD5 MAb or isotype control MAb. Data 
are mean ± SD (n = 3 mice), one representative experiment of three, *p < 0.05 




5.2.4 Increased activation-induced cell death and level of Fas receptor on 
CD8+ T cells after anti-CD5 MAb treatment   
 Increased T cell activation after CD5 blockade can lead to activation-
induced cell death (AICD). To assess whether anti-CD5 MAb treatment resulted 
in increased T cell AICD, cells isolated from draining lymph nodes and TILs were 
stained with FITC-annexin V and PI and anti-Fas receptor MAb. The fraction of 
CD8+ T cells undergoing AICD (Annexin V+/PI+) and early apoptosis (Annexin 
V+/PI-) was increased among CD8+ T cells in draining lymph nodes and tumours 
from anti-CD5-treated mice (Figure 29). Because Fas receptor/Fas ligand 
interaction is important for AICD (185), I further determined the level of Fas 
receptor on T cells. There was an increased level of Fas receptor on CD4+ T cell 
in draining lymph nodes (Figure 30A). Furthermore, treatment with anti-CD5 
MAb also induced an increase in the level of Fas on CD8+ T cells from draining 
lymph nodes and tumours, but not spleens, from anti-CD5-treated mice (Figure 

























Figure 29. Increased early apoptosis of CD8+ T cells apoptosis (upper 
graph) and late apoptosis (low graph) after treatment with anti-CD5 MAb. 
Draining lymph nodes (DLN) and TILs from tumour-bearing BALB/c mice that 
were treated with anti-CD5 MAb, stained for Annexin V and/or PI, and analyzed 
by flow cytometry. Data are mean ± SD (n = 3 mice), one representative 











Figure 30. The level of Fas receptor on CD4+ T cell and CD8+ T cells after 
treatment with anti-CD5 MAb in vivo. (A) The MFI of Fas receptor on CD4+ T 
cells isolated from spleens, draining lymph nodes, and tumours (TILs) excised 
from 4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb or 
isotype control MAb. (B) The MFI of Fas receptor on CD8+ T cells isolated from 
spleens, draining lymph nodes, and tumours (TILs) isolated from 4T1 tumour-
bearing BALB/c mice that were treated with anti-CD5 MAb or isotype control 
MAb. Data are mean ± SD (n = 3 mice), one representative experiment of three, 
ns, not significant, *p < 0.05 (Student’s unpaired one-tailed t-test), FMO = 




 5.2.5 Enhanced T cell tumour reactivity and degranulation after treatment 
with anti-CD5 MAb in vivo 
 I further determined cytotoxic T lymphocyte (CTL) effector function after 
treatment with anti-CD5 MAb in vivo. CTL effector function was assessed by flow 
cytometric measurement of a surrogate marker for CTL degranulation: the level 
of CD107a (188). The fraction of CD107a+CD4+ T cells and the mean 
fluorescence intensity of CD107a were significantly higher in spleens, draining 
lymph nodes, and tumours (TILs) from anti-CD5 MAb-treated mice (Figure 31A). 
Furthermore, the fraction of CD107a+CD8+ T cells among all CD8+ T cells in both 
spleens and draining lymph nodes (DLN) from mice treated with anti-CD5 MAb 
was significantly increased compared to mice treated with isotype control MAb 
(Figure 31B). The MFI was also significantly higher in spleens, DLN, and TILs in 
anti-CD5 MAb-treated mice (Figure 31B). In addition, antigen-specific activation 
of T cells was assessed using a surrogate marker for antigen-specific T cell 
activation: CD137, a member of the TNFR family with costimulatory function 
(189). Anti-CD5 MAb-treated mice had an increased fraction of CD137+CD4+ T 
cells in spleens and draining lymph nodes but not among TILs (Figure 32A). The 
MFI of CD137 was up-regulated in CD4+ TILs after treatment with anti-CD5 MAb 
(Figure 32A). Moreover, there was a significant increase in the fraction of 
CD137+CD8+ T cells in spleens and among TILs (Figure 32B). The numerical 
increase in the fraction of CD137+CD8+ T cells in DLN was not significant (Figure 
32B). The MFI of CD137 was significantly higher in CD8+ T cells in spleens, DLN, 




data suggest antigen-specific and effector functions of CD8+ T cells and CD4+ T 















Figure 31. The fraction of CD8+CD107a+ T and CD4+CD107a+ T cells after 
treatment with anti-CD5 MAb in vivo. (A) The fraction of CD4+CD107a+ T cells 
and MFI of CD107a on CD4+ T cells isolated from spleens, draining lymph 
nodes, and TILs from 4T1 tumour-bearing BALB/c mice that were treated with 
anti-CD5 MAb or isotype control MAb. (B) The fraction of CD8+CD107a+ T cells 
and MFI of CD107a on CD8+ T cells isolated from spleens, draining lymph 
nodes, and TILs isolated from 4T1 tumour-bearing BALB/c mice that were 
treated with anti-CD5 MAb or isotype control MAb. Data are mean ± SD (n = 3 
mice), one representative experiment of three, ns, not significant, *p < 0.05 












Figure 32. The fraction of CD8+CD137+ T and CD4+CD137+ T cells after 
treatment with anti-CD5 MAb in vivo. (A) The fraction of CD4+CD137+ T cells 
and MFI of CD137 on CD4+ T cells isolated from spleen, draining lymph nodes, 
and tumours (TILs) from 4T1 tumour-bearing BALB/c mice that were treated with 
anti-CD5 MAb or isotype control MAb. (B) The fraction of CD8+CD137+ T cells 
and MFI of CD137 on CD8+ T cells isolated from spleens, draining lymph nodes, 
and tumours (TILs) from 4T1 tumour-bearing BALB/c mice that were treated with 
anti-CD5 MAb or isotype control MAb. Data are mean ± SD (n = 3 mice), one 
representative experiment of three, ns, not significant, *p < 0.05 (Student’s 





5.2.6 No overt toxicity is associated with anti-CD5 MAb treatment in vivo 
 To determine whether in vivo administration of anti-CD5 MAb has any 
overt toxicity, I measured body weight for all groups of mice from the first day of 
antibody injection and monitored the weight over the course of the treatment. No 
toxicity by this relatively crude measure (decreased body weight compared to 
mice treated with isotype control MAb) was observed as indicated by the body 
weight when mice received single treatments or when they received a 































Figure 33. Body weight measurements. BALB/c mice bearing 4T1 tumours 
were treated with the indicated therapeutic modalities. Their body weights 
were measured and recorded regularly after treatments. Means and SDs of 












5.2.7 Mice treated with anti-CD5 MAb had significant accumulation of Treg 
cells in tumour-draining lymph nodes 
 Accumulation of myeloid-derived suppressor cells (MDSC) has been 
shown to suppress immunotherapy (64). In my model, I investigated the fraction 
of MDSC in spleens, DLN, and tumours (TILs) to determine if they were 
influenced by treatment with anti-CD5 MAb. The percentage of MDSC (Gr-
1+CD11b+) among all cells from spleens and tumours was significantly higher in 
mice harbouring 4T1 tumour cells compared to naïve mice but was not increased 
by treatment with anti-CD5 MAb (Figure 34A). The increase in MDSC in tumour-
bearing mice was observed only in spleen and in tumours and not in lymph 
nodes (Figure 34A). Tregs (CD4+/CD25+/FoxP3+) were also assessed, with an 
increase in the fraction of Tregs among all CD4+ T cells in the draining lymph 
nodes of mice treated with anti-CD5 MAb (Figure 34B). No differences in the 






























Figure 34. The fraction of Treg and MDSC after treatment with anti-CD5 MAb. 
(A) Spleens, lymph nodes, and tumours were collected at day 21 after 4T1 
implantation and treatment with anti-CD5 MAb and the fraction of MDSC in those 
organs assessed by flow cytometry. (B) Spleens, lymph nodes, and tumours 
were collected at day 21 after 4T1 implantation and treatment with anti-CD5 MAb 
and the fraction of Treg cells was assessed by flow cytometry. Data are mean ± 
SD (n = 3 mice), one representative experiment of three, ns, not significant, *p < 














5.2.8 Myeloid-derived suppressor cells express higher levels of inhibitory 
ligands in mice treated with anti-CD5 MAb 
 Although accumulation of MDSC was not significantly enhanced after 
treatment with anti-CD5 MAb, the levels of inhibitory ligands for PD-1 and Fas 
receptor were significantly higher in draining lymph nodes in mice treated with 
anti-CD5 MAb. The MFI of PD-L1 was higher in draining lymph nodes from mice 
treated with anti-CD5 MAb compared to the mice treated with isotype control 
MAb (0.3X103 versus 0.7X103, respectively, p < 0.05)(Figure 35A). In addition, 
the MFI of Fas ligand on MDSC from draining lymph nodes isolated from mice 
treated with anti-CD5 MAb was significantly higher compared to mice treated with 
isotype control MAb (0.14X103 versus 0.23X103, respectively, p < 0.05)(Figure 
35B). No differences were observed in the levels of inhibitory ligands in Tregs in 






































Figure 35. Level of PD-L1 and Fas ligand on MDSC. Draining lymph nodes 
were collected at day 21 after 4T1 implantation and treatment with anti-CD5 
MAb. The level of PD-L1 and Fas ligand on MDSC were assessed by flow 
cytometry. (A) PD-L1 MFI on MDSC isolated from draining lymph nodes. (B) Fas 
ligand MFI on MDSC isolated from draining lymph nodes. Data are mean ± SD (n 
= 3 mice), one representative experiment of three, *p < 0.05 (Student’s unpaired 















5.2.9 Increased fraction of activated CD8+ T cells in mice treated with anti-
CD5 + anti-PD-1 MAbs 
 PD-1 blockade decreases exhaustion in effector CD8+ T cells but does not 
increase activation. To investigate whether in vivo administration with anti-CD5 
MAb could enhance CD8+ T cell activation during anti-PD-1 treatment, I 
combined anti-CD5 and anti-PD1 treatment of mice (For treatment design see 
Figure 36C). The results show that addition of anti-CD5 MAb in combination with 
treatment with anti-PD-1 MAb significantly increased CD8+ T cell activation in 
both spleens and draining lymph nodes compared to single treatment with anti-
PD-1 MAb (14.2% vs 9.5% and 22.2% vs 14.7%, respectively; p<0.05; Figure 
36A). Furthermore, additional treatment of anti-CD5 MAb in combination with 
treatment with anti-PD-1 MAb significantly increased CD4+ T cell activation in 
both the spleen and draining lymph nodes compared to single treatment with 
anti-PD-1 MAb (25.7 vs 13.3% and 32.6% vs 22.7%, respectively; p<0.05; Figure 
36B). These data suggest that addition blockade of anti-CD5 enhances CD8+ T 























Figure 36. The fraction of CD8+CD69+ T and CD4+CD69+ T cells after 
treatment with anti-CD5 MAb and anti-PD1 in vivo. (A) The fraction of 
CD8+CD69+ T cells in spleens, draining lymph nodes, and tumours (TILs) from 
4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb and anti-
PD-1 MAb. (B) The fraction of CD4+CD69+ T cells from spleens, draining lymph 
nodes, and tumours (TILs) isolated from 4T1 tumour-bearing BALB/c mice that 
were treated with anti-CD5 MAb and anti-PD-1 MAb. (C) treatment design. Data 
are mean ± SD (n = 3 mice), one representative experiment of three, *p < 0.05, 












5.2.10 Increased fraction of effector CD8+ T cells after anti-CD5 and anti-PD-
1 combination therapy 
 I further assessed whether addition of anti-CD5 MAb to anti-PD-1 MAb 
could increase effector T cell activation. I observed an increase in the fraction of 
CD107a+CD8+ T cells in spleens and draining lymph nodes in mice treated with 
anti-CD5 + anti-PD-1 MAbs (Figure 37A). Furthermore, the fraction of 
CD107a+CD4+ T cells isolated from spleens and draining lymph nodes was 
higher in mice treated with combination therapy (anti-CD5 + anti-PD-1 
MAbs)(Figure 37B). In addition, the surrogate marker for antigen-specific CD8+ T 
cells (CD137) was assessed. The data show that the fraction of CD137+CD8+ T 
cells isolated from spleens and draining lymph nodes was significantly higher in 
mice treated with anti-CD5 MAb and anti-PD-1 MAb compared to single 
treatment alone (Figure 38A). The fraction of CD137+CD4+ T cells isolated from 
spleens and draining lymph nodes was also significantly higher in mice treated 




























Figure 37. The fraction of CD8+CD107a+ T and CD4+CD107aء T cells after 
treatment with anti-CD5 MAb and anti-PD1 in vivo. (A) The fraction of 
CD8+CD107a+ T cells isolated from spleens, draining lymph nodes, and tumours 
(TILs) isolated from 4T1 tumour-bearing BALB/c mice that were treated with anti-
CD5 MAb and anti-PD-1 MAb. (B) The fraction of CD4+CD107a+ T cells from 
spleens, draining lymph nodes, and tumours (TILs) isolated from 4T1 tumour-
bearing BALB/c mice that were treated with anti-CD5 MAb and anti-PD-1 MAb. 
Data are mean ± SD (n = 3 mice), one representative experiment of three, ns, not 































Figure 38. The fraction of CD8+CD137+ T and CD4+CD137+ T cells after 
treatment with anti-CD5 MAb and anti-PD1 in vivo. (A) The fraction of 
CD8+CD137+ T cells isolated from spleens, draining lymph nodes, and tumours 
(TILs) isolated from 4T1 tumour-bearing BALB/c mice that were treated with anti-
CD5 MAb and anti-PD-1 MAb. (B) The fraction of CD4+CD137+ T cells from 
spleens, draining lymph nodes, and tumours (TILs) isolated from 4T1 tumour-
bearing BALB/c mice that were treated with anti-CD5 MAb and anti-PD-1 MAb. 
Data are mean ± SD (n = 3 mice), one representative experiment of three, *p < 












5.2.11 Treatment with anti-CD5 MAb in vivo reduced 4T1 tumour growth in 
mice  
          To further test the hypothesis, I used anti-CD5 MAb as a single agent, 
combined with anti-PD-1 MAb, and combined with chemotherapeutic treatment in 
mice bearing 4T1 tumours to examine their affect in suppressing tumour growth. I 
found that treatment with anti-CD5 alone did not reduce tumour growth (Figure 
39A for treatment design; B for tumour volume). I further tested anti-CD5 in 
combination with anti-PD-1 MAb and found no significant delay in tumour growth 
(Figure 39A and B). I then reduced the number of dosages to one injection only 
of anti-CD5 MAb followed by three dosage of anti-PD-1 MAb and found a trend in 
tumour delay that was not reproducible (Figure 40A for treatment design; B for 
tumour volume). I have shown previously that the 4T1 model has increased 
accumulation of MDSCs in spleens and in 4T1 tumours (Figure 34) which are 
associated with reduced response to immunotherapeutic agents (64). Therefore, 
MDSC-depleting drugs such as gemcitabine (190) and 5-FU (70) were next 
tested in combination with anti-CD5 MAb. The data show delayed tumour growth 
in mice treated with gemcitabine alone, but anti-CD5 MAb treatment did not 
enhance gemcitabine-mediated anti-tumour activity (Figure 41). I then tested 5-
FU in combination with anti-CD5 MAb and changed the route of administration 
for anti-CD5 MAb from intraperitoneal (i.p.) to peritumoural injection (p.t) to 
determine if local administration of anti-CD5 MAb resulted in enhanced tumour 




exhaustion and AICD. Similar to gemcitabine, 5-FU alone reduced tumour growth 
but anti-CD5 MAb treatment did not enhance 5-FU-mediated anti-tumour activity 
(Figure 42).  
 Another experiment was conducted to test the capacity of anti-CD5 MAb 
to affect tumour homograft growth in mice in vivo under different conditions: 
treatment with lower dosages of anti-CD5 MAb and inoculation with a lower 
number of 4T1 tumour cells (that, regardless, result in 100% tumour take). On 
day 0, mice were injected with 5000 4T1 tumour cells. In addition, they were 
treated with anti-CD5 MAb every 3 to 4 days for a total of 11 injections with MAb 
(euthanasia of mice when those with the largest tumours reached maximal 
tumour volume allowable according to humane animal management protocols as 
required by the Western University Animal Care Committee, the Canadian 
Council on Animal Care, and the approved protocol under which the experiment 
was conducted). Tumours volumes were estimated as described in Materials and 
Methods. The resulting data are shown in Figure 44.  These data indicate that, 
anti-CD5 MAb administration in vivo did reduce 4T1 tumour growth in mice when 



















Figure 39: Treatment with anti-CD5 MAb + anti-PD-1 MAb, first treatment 
design. 4T1 tumour-harbouring mice received anti-PD-1 and anti-CD5 MAbs 7 
days after tumour inoculation and anti-CD5 MAb every three days. (A) Scheme 
for treatment plan. (B) Tumour volume. Data are mean ± SEM (n = 5 mice), one 
representative experiment of three, ns, not significant (Student’s unpaired one-


























Figure 40: Treatment with anti-CD5 MAb + anti-PD-1 MAb, second treatment 
design. 4T1 tumour-harbouring mice received anti-CD5 MAbs 7 days after 
tumour inoculation followed by anti-PD-1 MAb every three days. (A) Scheme for 
treatment plan. (B) Tumour volume. Data are mean ± SEM (n = 6 mice), one 
representative experiment of three, ns, not significant (Student’s unpaired one-























Figure 41: Treatment with anti-CD5 MAb + Gemcitabine. 4T1 tumour-
harbouring mice received Gemcitabine 7 days after tumour inoculation and 
followed by one dosage of anti-CD5 MAb after three days. (A) Scheme for 
treatment plan. (B) Tumour volume. Data are mean ± SEM (n = 6 mice), one 

















Figure 42: Treatment with anti-CD5 MAb + 5-FU. 4T1 tumour-harbouring mice 
received 5-FU and anti-CD5 MAb 7 days after tumour inoculation and anti-CD5 
MAb every three days. (A) Scheme for treatment plan. (B) Tumour volume. Data 
are mean ± SEM (n = 6 mice), one experiment, *p < 0.05 (Student’s unpaired 

































Figure 43: Treatment with low dosage of anti-CD5 MAb. 4T1 tumour-
harbouring mice received 25 ug/mouse of anti-CD5 MAb on day 0 along with 
tumour inoculation and continued to receive the treatment of a total of 11 
injections (A) Scheme for treatment plan. (B) Tumour volume. Data are mean ± 
SEM (n = 7 mice), one representative experiment of two, *p < 0.05 (Student’s 





Chapter 6  
6.1 Discussion  
           CD5 is highly expressed on human leukemic cells, including leukemias 
arising in T and B cell populations (191). As an antigen preferentially and 
selectively expressed in leukemia, it has been therapeutically targeted in an 
antibody-drug conjugate approach using anti-CD5 MAb conjugated to toxin (165, 
167, 192). More recently, in addition to molecule-based anti-CD5 cancer 
immunotherapy, cell-based anti-CD5 therapy has been introduced in the form of 
CAR-T cells engineered to target CD5 on human T and B cells to treat leukemias 
arising from these immune cell types (129) and a clinical trial has been launched 
targeting CD5 in CD5+ cancer cells using CD5 CAR-T cells (NCT03081910) 
(193) with recent published result demonstrate the safety and positive outcome 
with the treatment (illustrated in section 1.8 pf this thesis) (168). In addition, CAR-
T cells engineered to lack CD5 expression have been generated to prevent 
fratricide (i.e., CAR T cell-mediated ablation of CD5-expressing effector CAR T 
cells) and enhance the potential value of anti-CD5 CAR T cell approaches (132).  
            With respect to CD5 on normal T cells, less is known but data suggest 
that lack of CD5 activity increases anti-tumour immune surveillance and reduces 
tumour growth (As illustrated in detail in section 1.6 of this thesis). This suggests 




immunity and enhanced T cell activation. Thus, CD5 expression on non-solid 
tumours has been the focus of therapy. 
             In this thesis, I aimed to understand the relationship between CD5 and T 
cell activation and exhaustion and investigate the effect of targeting CD5 using 
monoclonal antibody ex vivo and in vivo on immune T cell and tumour growth. 
CD5 has been shown to interact with TCR and impair TCR signaling (89, 105). 
Previous studies have shown a correlation between CD5 and anti-tumour 
immunity where CD5 knockout mice inoculated with B16F10 melanoma cells had 
delayed tumour growth compared to wild type mice (134). However, the 
correlation between CD5 level and T cell activation and exhaustion in tumours 
and in peripheral organs is ill-defined and requires further investigation. In 
Chapter Three of this thesis, I determined the in vivo relationship between T cell 
CD5 level and T cell activation and exhaustion in primary mouse T cells isolated 
from different organs and syngeneic tumours. I found different patterns of CD5 
expression in T cells isolated from different tissues in mice bearing tumour 
homografts. The differences in CD5 expression patterns correlated with the level 
of T cell activation and exhaustion in different organs and tumours. First, I 
determined CD5 levels in T cell subsets isolated from lymphoid organs and the 
tumour. CD5 expression was observed in T cell subsets including CD4+ T cells 
and CD8+ T cells: CD4+ T cells were found to express greater amounts of CD5 
than CD8+ T cells.  
 CD5 is associated with the TCR/CD3 complex and BCR and has been 




associated with B cell activation (194) and is found to be expressed on certain 
lymphoid tumours (91). I investigated CD5 levels on mouse CD8+ T cells during 
naïve, ex vivo activation and in vivo activation to determine their pattern of 
expression. My data reveal that T cell CD5 levels are enhanced following 
recognition of specific target (exposure to tumour antigen or stimulation with anti-
CD3/anti-CD28 MAbs)(177)). Primary CD8+ T cells isolated from mice, activated 
ex vivo or in vivo by exposure to anti-CD3 and anti-CD28 MAbs or tumour cells, 
had an increased level of CD5 compared to non-activated CD8+ T cells. This is 
consistent with published data linking increased CD5 expression to the strength 
of T cell receptor signaling and function: a mechanism to fine-tune TCR signaling 
(89). My results indicate a clear correlation between CD5 and T cell activation. 
Considering that CD5 is associated with TCR and BCR (76, 195), this agrees 
with a published report that CD5 is indicator of B cell activation (194). 
Furthermore, I report that T cell subsets from mouse spleen and lymph nodes 
display similar CD5 levels. However, the fraction of both CD4+ and CD8+ T cell 
subsets infiltrated into tumours had a reduced level of CD5. Although I did not 
distinguish between the possibilities that T cells with reduced CD5 prior to 
infiltration into tumours were preferentially recruited into tumours, or that T cells 
with elevated CD5 infiltrated into tumours but had their CD5 levels reduced once 
they were within tumours, CD5 levels in T cells have been reported to be induced 
in correlation with the intensity of antigen recognition by TCR (76). Mouse 4T1 
tumours are poorly immunogenic and highly metastatic (64), providing a context 




tumours. That, along with our observation of reduced CD5 on T cells within the 
tumour and our previous report that experimental reduction of CD5 leads to 
increased CD8+ T cell activation (177), collectively suggest that T cells with low 
CD5 within tumours (due wholly or in part to the poorly immunogenic 
characteristic of 4T1 tumours) may have increased sensitivity to poorly 
immunogenic 4T1 tumour antigens. These results demonstrated that CD5 may 
be downregulated in T cells based on the TCR/CD3 signaling intensity within 
tumours.  
 I further tested T cell activation in relation to CD5 expression levels in 
spleens, lymph nodes, and 4T1 tumours. In lymphoid organs, the fraction of 
CD69+CD5high CD4+ T and CD69+CD5high CD8+ T cells were significantly higher 
than the fraction of CD69+CD5low CD4+ T and CD69+CD5low CD8+ T cells, 
respectively. This suggests that CD5 levels increase on T cells as TCR 
stimulation proceeds and T cells undergo activation (as evidenced by increased 
CD69, an early marker of T cell activation). Interestingly, only the CD4+ and CD8+ 
T cells in the tumour with low/undetectable CD5 expression exhibited higher 
levels of activation compared to CD5high TILs: an observation in accord with our 
previous report that inhibition of CD5 on T cells leads to enhanced T cell 
activation and proliferation (177) and suggesting that intra-tumoural T cells with 
naturally-occurring low CD5 are selected for increased presence within 4T1 
tumours. Furthermore, CD5 has been reported to protect tumour-reactive 
circulating T cells from activation-induced cell death (AICD) following recognition 




tumour may be evidence of selection of T cells with naturally-occurring low CD5 
for enhanced activation and proliferation within tumours: such selection would 
promote interaction between T cells and tumour cells, enhance the TCR 
signaling response, and result in increased activation as shown by increased 
CD69 expression. This is consistent with a report of increased anti-tumour 
cytolytic activity in T cells with low CD5 levels (136). The mechanism regulating 
expression in vivo is not well understood and it is difficult, with our present level 
of understanding, to elucidate the reasons underlying our observation of T cells 
with reduced CD5 within tumours compared to T cells from lymph nodes and 
spleens. Regardless of that, low CD5 on T cells within tumours can conceivably 
lead to increased anti-tumour immune activity. 
     T cell exhaustion is mediated by the duration and magnitude of antigenic 
activation (196). The expression of PD-1 by T cells is one measurement for T cell 
exhaustion (197) and binding to its ligand results in limitation of T cell function 
(198). In this report I show that CD5 might protect T cell from exhaustion in the 
tumour through downregulation of PD-1. Indeed, our results indicate that the 
number of PD-1+CD5-/lowCD8+ TILs within tumours was significantly higher than 
PD-1+CD5highCD8+ TILs. However, this was not the case with intra-tumoural 
CD4+ TILs, where there was no observation of downregulated CD5 in an 
increased fraction of this PD-1+ subset of T cells in tumours compared to the 
same subset in lymph and spleen. This may be due to the fact that PD-1 is 
upregulated when T cells are chronically exposed to non-self tumour antigens 




CD8+ T cells, making them preferentially susceptible to PD-1 upregulation after 
exposure to tumour antigen. CD4+ T cells, on the other hand, do not recognize 
tumour cell directly due to the lack of MHC II on solid tumour cells (199). 
Therefore, they may not upregulate exhaustion markers when they are activated 
due to limited interaction with tumour cells.  
      Taken together, our data suggest that CD5 levels on T cells (particularly 
CD8+ T cells) are correlated with T cell activation and exhaustion, as evidenced 
by the relationship between CD69 and PD-1: that correlation is evidence 
supportive of a role for CD5 in T cell survival. CD5 is induced based on the 
intensity of the TCR-MHC-1 interaction and poorly immunogenic tumour that can 
lead to T cells with reduced CD5: a situation promoting increased TCR-MHC-I 
interaction and enhanced T cell activation. A causal role for CD5 in T cell 
activation, supported by evidence presented here and by published previously 
(177), forms the basis to propose targeting of CD5 as a therapeutic intervention 
to enhance anti-tumour immunity. Immune checkpoint blockade is a current 
immunotherapeutic approach in cancer that is most effective in patients with an 
increased fraction of PD-1+ cells (200). Therapeutic interventions that lead to 
enhanced activation of T cells in the tumour (for example, interventions to reduce 
CD5) may be suitable components of combination therapy that include anti-CD5 
treatment with immune checkpoint blockade: anti-CD5 would lead to increased 
PD-1 on tumour-resident T cells that, in turn, would lead to a situation promoting 
the effectiveness of anti-PD-1 immune checkpoint blockade. The current study 




tumour-associated CD8+ T cells and suggests a therapeutic approach to 
sensitize T cell to immune checkpoint blockade.  
The first report of anti-CD5 MAb-based therapy of tumours grown as solid 
tumours involved the effect of administration of anti-CD5 in mouse CD5+ 
leukemias grown as solid tumour homografts (133). Mice injected 
subcutaneously with CD5+ mouse leukemia tumours or CD5- mouse lung cancer 
cells had increased overall survival when treated with anti-CD5 treatment. This 
effect was abolished in thymectomized mice, suggesting that that the therapeutic 
effect of anti-CD5 MAb effects was mediated, not by direct effects on CD5+ 
tumour cells, but on thymus-derived CD5+ cells including non-tumour host mouse 
T cells. Further studies have shown that homografted mouse tumours grown in 
CD5 knockout (CD5-/-) mice grow more slowly than in wild type CD5+/+ mice 
(134).This suggests that reducing CD5 signaling could lead to enhanced anti-
tumour immunity. Assessment of the effect of direct administration of anti-CD5 
MAb to block CD5 signaling on CD8+ T cells will lead to increased understanding 
of the effect of CD5 blockade in tumour immunity and facilitate the development 
of CD5-targeted anticancer immunotherapy. In chapter four, I investigated the 
direct effect of using anti-CD5 MAb on CD8+ T cell activation and function ex 
vivo. 
             To investigate the effect of anti-CD5 MAb of CD8+ T cell activation and 
function I treated primary CD8+ T cells isolated from mice homografted (tumour-
harbouring) and tumour-naïve (non-tumour bearing) with anti-CD5 MAb ex vivo. 




treatment with an antagonistic anti-CD5 MAb increased the fraction of CD8+ T 
cells expressing markers of activation (CD69 and IFNy) (201, 202) and increased 
CD8+ T cell proliferation, indicating that anti-CD5 MAb enhances CD8+ T cell 
activation. Ex vivo treatment with anti-CD5 MAb alone did not induce CD8+ T cell 
activation suggesting that anti-CD5 treatment mediates enhanced activation by 
influencing CD5 effects on TCR signaling. In further support of this concept, ERK 
phosphorylation (indicative of increased TCR signaling) was increased in cells 
activated by treatment with anti-CD3, combined with treatment with anti-CD5 
MAb, compared to activation with anti-CD3 alone. Treatment with anti-CD5 alone 
did not lead to increased ERK phosphorylation. This is consistent with a report 
that activation of ERK was greater in thymic cells from mice that express 
unfunctional CD5 challenged with OVA323-339-peptide to induce T cell 
activation compared to thymic cells from CD5 wildtype mice (183). 
           My data show increased AICD (a consequence correlated with increased 
T cell activation (20, 184)) in activated CD8+ T cells treated with anti-CD5 MAb. 
In addition, and consistent with increased AICD, treatment of spleen cells 
increased the fraction of FasR+ and FasL+ T cells; TILs isolated from tumour-
bearing mice with CD5 deficiency have been reported to be similarly susceptible 
to AICD via increased FasR expression (134). AICD can occur as result of over-
stimulation of TCR (184). CD5 acts to fine-tune TCR responsiveness and, 
therefore, blockade of CD5 could lead to enhance TCR sensitivity to antigen and 
increased AICD. Based on these data showing that blocking CD5 on activated T 




shown by elevated CD69, and enhanced production of IFNγ ex vivo, and that 
activation is associated with increased proliferation as shown by CFSE, I 
proposed that administration of blocking anti-CD5 MAb could enhance anti-
tumour immunity. In a cytotoxic T cell lysis (CTL) assay, I observed that CD8+ T 
cells treated with anti-CD5 MAb were more capable of targeting and killing 
mouse 4T1 tumour cells ex vivo than cells treated with control Ab. These data 
strongly suggest that treatment with anti-CD5 MAb can increase the ability of 
CD8+ T cells to target and eliminate tumour cells, and supports the concept that 
blocking CD5 to enhance anti-tumour CD8+ T cell function has potential as an in 
vivo anti-cancer immunotherapy. Blocking CD5 on CD8+ T cells could lead to 
hyper-activation that, although potentially desirable in increasing anti-tumour 
action in the short term, could increase inhibitory receptors that, over time, act to 
suppress CD8+ T cell function. Therefore, targeting additional T cell molecules in 
combination with CD5 blockade (for example, immune checkpoint molecules) 
may be necessary to prevent CD8+ T cell exhaustion and sustain CD8+ T cell 
function. With due consideration of additional effects, my data nevertheless show 
that blockade of CD5 on T cells ex vivo has promise as an anti-tumour 
immunotherapy.  
          The data described in Chapter Four reveal that blocking CD5 ex vivo 
results in increased CTL activation and tumour cell cytotoxicity (now published in 
the European Journal of Immunology (177)). In Chapter Five, I aimed to assess 
the consequences of administration of anti-CD5 MAb to tumour-bearing mice on 




and to determine whether blocking CD5 in vivo could increase activation of 
normal T cells and enhance detection of poorly immunogenic tumour antigen(s). 
The triple-negative 4T1 mouse breast tumour cell line was used as a model for 
poorly immunogenic and highly metastastatic tumours, reflecting similar breast 
tumours in humans (174). This makes them good candidates to determine 
whether anti-CD5 MAb delivered in vivo could enhance T cell activation and 
ability to recognize poorly immunogenic tumour antigens. Mice were injected with 
4T1 mouse tumour cells and treated with anti-CD5 MAb. The activation and 
function of T cells isolated from spleens, draining lymph nodes, and tumours 
(tumour-infiltrating lymphocytes, or TILs) were further assessed using flow 
cytometry. 
       The data show that administration of anti-CD5 MAb in vivo increases the 
ratio of CD8+ to CD4+ T cells in draining lymph nodes and within tumours. The 
predominant numbers of CD8+ T cells and the minority CD4+ T cells were 
significantly activated in spleens, draining lymph nodes, and TILs, suggesting 
that anti-CD5 treatment mediates enhanced activation by influencing CD5 effects 
on TCR signalling. As a result of increased activation, the level of the exhaustion 
marker PD-1 and the fraction of PD-1+CD4+ T cells and PD-1+CD8+ T cells were 
significantly higher after treatment with anti-CD5 MAb. The data was consistent 
with our previous report showing increased activation-induced cell death (AICD) 
and early apoptosis in CD8+ T cells after treatment with anti-CD5 MAb ex vivo 
(177). I showed significantly increased AICD and early apoptosis in CD8+ T cells 




AICD, treatment with anti-CD5 blocking MAb increased the level of Fas receptor 
on the surface of CD8+ T cells.  Because AICD occurs after chronic stimulation of 
T cell receptors (TCRs)(184), treatment with anti-CD5 MAb may lead to TCR 
sensitivity to tumour antigen, resulting in increased AICD. These results suggest 
that treatment with anti-CD5 MAb could also enhance the effector function of T 
cells. I found significantly increased T cell effector function in response to anti-
CD5 treatment in spleens, draining lymph nodes, and TILs as shown by 
increased expression of surrogate markers of T cell degranulation and antigen-
specific T cell (CD107a and CD137). Together, these data suggest that treatment 
with non-depleting anti-CD5 MAb in vivo resulted in increase T cell activation, 
AICD, and effector function. 
 I further tested the fraction of suppressor cell such as Tregs and MDSC 
after treatment with anti-CD5 MAb in vivo. I found that the fraction of MDSC did 
not increase after treatment with anti-CD5, but was influenced by the 4T1 tumour 
inoculation in the spleen and the tumour bed. Tregs, on the other hand, were 
significantly enhanced in lymph nodes after treatment with anti-CD5 MAb in vivo. 
Although the fraction of myeloid-derived suppressor cells (MDSC) was not 
altered upon anti-CD5 MAb treatment, the inhibitory ligands FasL and PD-L1 
were significantly higher in the draining lymph nodes (DLN) from anti-CD5-
treated mice. These data suggest that inhibitory signaling could affect T cell 
immunity in the 4T1 breast tumour model treated with anti-CD5 MAb. 
Furthermore, I tested whether combined treatment with anti-CD5 MAb and anti-




treatment with anti-PD-1 MAb. The results show that treatment with both anti-
CD5 MAb with anti-PD-1 MAb enhanced T cell activation and function compared 
to single treatment with anti-PD-1 in the spleen and DLN.  
 Administration of anti-CD5 in vivo results in significantly increased 
numbers of CD8+ cells relative to CD4+ T cells and enhanced CD8+ T cell 
activation and effector function. To assess whether administration of anti-CD5 
MAb can significantly delay in tumour growth, I evaluated several approaches. 
The first approach was to administer anti-CD5 MAb i.p. on day 7 after 4T1 
tumour inoculation (Figures 4,5, 39, and 40). Although there was a trend toward 
tumour growth delay in one experiment, the result was not reproducible upon 
repetition. This could be due to several factors. First, there was a significant 
accumulation of immune suppressor cells in the 4T1 tumour cell model (Tregs and 
MDSC (203) and  Figure 34). It has been previously reported that the 4T1 tumour 
model is resistant to immunotherapeutic approaches (64) and the authors 
suggested combining several approaches to suppress the growth of 4T1 tumours 
in vivo when treating with immunotherapies: possible additional approaches 
could include depletion of MDSC or combining immunotherapeutic drugs with 
chemotherapeutic drugs toxic to immunosuppressive cell populations (64). To 
address this question, I tested the third approach (Figures 6, 7, 41 and 42) by co-
administering two drugs used to deplete MDSCs in vivo: 5-fluorouracil (5-FU) and 
the deoxycytidine analogue and antimetabolite gemcitabine. Although single 
doses of these drugs resulted in tumour delay, the combination of 5-FU or 




compared to single treatment with either of the two drugs. Second, and similar to 
ex vivo results (177), I observed increased AICD in T lymphocytes in response to 
anti-CD5 MAb treatment: a consequence of increased activation in CD8+ T cells 
from mice treated with anti-CD5 MAb. This observation was associated with 
increased Fas receptor levels in CD8+ T cells. This was expected as increased 
activation of CD8+ T cells has been shown to associate with increased levels of 
Fas receptor and AICD (204). To overcome this limitation, I tested the fifth 
approach: that is, by reducing the dose of anti-CD5 MAb used to treat homograft 
tumors in vivo and administered CD5 MAb as early as day 0. In addition, the 
route of CD5 MAb administration was peritumoural to limit systemic 
overactivation of T cells and reduce the chance of developing AICD (Figure 8 
and 43). This approach gave the best result in delaying tumour growth in vivo as 
a single treatment of anti-CD5 MAb (Figure 43).  
            Considering that CD5 is expressed on all T cells, treatment with anti-CD5 
MAb could have multiple effects, including adverse consequences: such possible 
consequences require further investigation. It has been reported that B6 
polyclonal T cells with no or low CD5 expression are less capable of generating 
induced Tregs (iTregs) under certain conditions (205) which play a role in 
suppressing immune cells: anti-CD5 MAb administration could, therefore, result 
in adverse auto-immune effects. On the other hand, other have reported that 
generation of Tregs is not affected by the absence of the CK2 binding domain in 
CD5, suggesting that reduced CD5 activity have little or no Treg effects (182). It is 




Tregs, but that deletion of part of the CD5 molecule functional in affecting TCR 
signaling, or temporary blockade of the CD5 signaling pathway, would have little 
effect on generation of Tregs and reduced danger of induction of autoimmune 
effects. Nevertheless, multiple immune cell types (B cells, dendritic cells, and 
others) have been reported to express CD5 (146, 161, 206)  and the 
consequences of systemic administration of anti-CD5 capable of blocking CD5 
function on both anti-tumour CD8+ T cells (with potential to enhance anti-tumour 
immunity) and other immune cells (where blockade may have adverse effects) 
requires further study. 
 The use of toxic molecule-conjugated anti-CD5 depleting MAb was 
studied to treat CD5+ non-solid tumours. However, the impact of CD5 blocking 
antibody on normal T cells in CD5- solid tumours is not well illustrated. Despite 
the study that was conducted 1984 that shows continues administration of CD5 
polyclonal antibodies to slow the growth of EL lung cancer (133) there has been 
no further reports of the consequences of administration of anti-CD5 MAb for 
normal T cells in vivo to enhance its function. This thesis is the first to describe 
the correlation between CD5 and T cell activation and exhaustion in lymphoid 
organs and tumour and assess the affect of blocking CD5 function ex vivo in 
normal T cell to increase their activation and function. In addition, it illustrates the 
phenotypic changes in immune cell subsets in lymphoid organs as well as within 
tumours after in vivo administration of anti-CD5 MAb.  These results require 
further investigation, particularly in combination with current anti-tumour 




consideration as high dosage could results in unwanted high activation of CD8+ T 
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